Document:

MNK Exhibit 10.2 06.27.14

Exhibit 10.2
    
SEPARATION OF EMPLOYMENT AGREEMENT AND GENERAL RELEASE

THIS SEPARATION OF EMPLOYMENT AGREEMENT AND GENERAL RELEASE (“Agreement”) is by and between Steve Merrick (“Executive”) and Mallinckrodt Enterprises LLC, by and on behalf of itself, as plan sponsor (the “Company”).

WHEREAS, Executive is employed by the Company as Senior Vice President and President, Commercial Operations, International;

WHEREAS, Executive is a Participant in the Mallinckrodt Pharmaceuticals Severance Plan for U.S. Officers and Executives (“Plan”) which provides for certain benefits in the event Executive’s employment is terminated on account of a reason set forth in the Plan, subject to the terms of the Plan;

WHEREAS, Executive and the Company mutually desire to terminate Executive’s employment on an amicable basis, such termination to be effective July 16, 2014 (“Termination Date”); and

WHEREAS, in connection with the termination of Executive’s employment and pursuant to the terms of the Plan, the parties have agreed to a separation package and the resolution of any and all disputes between them.

NOW, THEREFORE, IT IS HEREBY AGREED by and between Executive and the Company as follows:

1.Benefits Upon Termination of Employment.  Whether or not Executive signs this Agreement, Executive will be entitled to the following:

(a)Earned But Unpaid Amounts.  Subject to the provisions of the paragraph entitled “Deductions for Amounts Owed to Company,” Executive shall receive any amounts earned, accrued or owing but not yet paid to Executive as of the Termination Date including, but not limited to, unused accrued vacation and unpaid base salary earned by Executive through the Termination Date.  Payment of these amounts shall be included in the first payroll check after the Termination Date.

(b)Notice Pay.  Executive was provided notice of his separation on June 16, 2014.  Executive shall perform all regular duties until the Termination Date unless relieved of some or all of such duties by Executive’s supervisor.  The Company shall pay Executive his regular base pay, minus any applicable deductions or withholdings, for work performed through the Termination Date, and will pay the equivalent of his regular base pay, minus any applicable deductions or withholdings, from the Termination Date through July 16, 2014, to fulfill the notice pay requirement in Section 4.01(a) of the Plan.  Executive acknowledges amounts payable under this section fully and completely satisfy the notice pay requirement set forth in Section 4.01(a) of the Plan.  Unless otherwise provided under applicable law, Executive will not be eligible to apply for short- or long-term disability or workers’ compensation at any time after the Termination Date.

(c)Equity Awards.  Except as otherwise set forth herein, the terms of the applicable award agreement shall govern Executive’s rights with respect to any equity awards held by Executive as of the Termination Date.  The vesting of all outstanding equity awards, and the ability to exercise any stock options, shall be governed by the terms of the applicable award agreement.  To obtain more information about equity holdings, Executive should contact UBS Financial Services through its web site at https://onesource.ubs.com/mnk or by calling 1-855-896-9404.

(d)Mallinckrodt Pharmaceuticals Retirement Savings and Investment Plan.  Executive shall be fully vested in Company contributions made to the Mallinckrodt Pharmaceuticals Retirement Savings and Investment Plan (“RSIP”) on behalf of the Executive, subject and pursuant to the terms of the RSIP.  Executive acknowledges that, as of the Termination Date, Executive shall cease to be eligible to participate in the RSIP and will not be eligible to make contributions or receive allocations of employer contributions after such date, unless otherwise provided by the terms of the RSIP.  To obtain more information about the RSIP, Executive should contact the RSIP’s third party administrator, Mercer HR Services, through its web site at www.ibenefitcenter.com or by calling the Mallinckrodt Pharmaceuticals Retirement Service Center at 1-800-722-2038.

(e)Mallinckrodt Pharmaceuticals Supplemental Savings and Retirement Plan.  If Executive participates in the Mallinckrodt Pharmaceuticals Supplemental Savings and Retirement Plan (“SSRP”), Executive 

shall be fully vested in Company contributions, if any, made to the SSRP on behalf of Executive, subject and pursuant to the terms of the SSRP.  Executive acknowledges, as of the Termination Date, Executive shall cease to be eligible to participate in the SSRP and will not be eligible to make contributions or receive allocations of employer contributions after such date, unless otherwise provided by the terms of the SSRP.  Payment of Executive’s SSRP account will be made in accordance with the terms of the SSRP.  To obtain more information about the SSRP, Executive should contact the SSRP’s third party administrator, Mercer HR Services, through its web site at www.ibenefitcenter.com or by calling the Mallinckrodt Pharmaceuticals Retirement Service Center at 1-800-722-2038.

(f)COBRA Continuation Coverage.  Executive (and Executive’s spouse, domestic partner or child(ren), as applicable) shall be eligible for continued coverage under the Company’s group health plans as required by and pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”).  Executive acknowledges the Company will provide COBRA coverage only if such coverage is timely elected by Executive (or other qualified beneficiary as defined by COBRA) and Executive is solely responsible for electing such coverage.  If Executive does not elect COBRA coverage timely, Executive will not be eligible to receive COBRA coverage.  Executive will be required to pay the entire premium for COBRA coverage and acknowledges COBRA coverage will end upon the expiration of the maximum period required under COBRA or earlier than such time if Executive does not pay the required premium within the applicable time period, if Executive terminates COBRA coverage, or if an event occurs that, pursuant to COBRA, permits the earlier termination of COBRA coverage.

2.Consideration to Executive for Signing This Agreement.  In consideration for Executive signing this Agreement, and pursuant to the terms of the Plan, the Company agrees to provide Executive with severance benefits, in addition to those benefits described in the section entitled “Benefits Upon Termination of Employment,” and modify certain benefits described in such section as follows:

(a)Salary Continuation Payment.  As soon as is administratively possible after the later of the Termination Date or the end of any applicable revocation period for this Agreement, Executive will begin receiving eighteen (18) months of salary continuation payments (the period during which this will be paid shall hereinafter be referred to as the “Severance Period”) at a bi-weekly gross rate of $14,230.77 (with total payments equaling $555,000.00), minus any applicable deductions or withholdings or other reductions provided for under the Plan or required by applicable law, which will be payable in a manner and on days that correspond to the Company’s regular paydays and payroll practices.  The first payment made pursuant to this paragraph may exceed a full pay period if it covers the period from the Termination Date through the date of the first payment.  In this case, any subsequent payments made during the Severance Period will cover full pay periods and only include a partial pay period if necessary to pay any remaining salary continuation payments.  Executive expressly authorizes the Company to make any necessary deductions, withholdings, or other reductions from amounts paid pursuant to this paragraph.

(b)Severance Period Bonus.  During the Severance Period, Executive will receive Executive’s Annual Bonus (as that term is defined in the Plan) at a bi-weekly gross rate of $5,192.31 (with total payments equaling $202,500.00), minus any applicable deductions or withholdings or other reductions provided for under the Plan or required by applicable law, which will be payable in a manner and on days that correspond to the Company’s regular paydays and payroll practices.  Executive expressly authorizes the Company to make any necessary deductions, withholdings, or other reductions from amounts paid pursuant to this paragraph.  

(c)Accelerated Vesting of Stock Options.  All stock options held by Executive as of the Termination Date which would have vested during the twelve (12) consecutive month period occurring immediately after the Termination Date shall accelerate and become immediately vested on the Termination Date.  All outstanding stock options held by Executive that are vested and exercisable as of the Termination Date (including amounts that vest pursuant to the provisions of this Agreement) shall be exercisable for the greater of (i) the period set forth in the applicable award agreement, or (ii) twelve (12) months from the Termination Date.  In no event, however, shall an option be exercisable beyond its original term.

(d)Accelerated Vesting of Restricted Stock, Restricted Units and Performance Units.  All unvested restricted stock, restricted units and performance units held by Executive as of the Termination Date which would have vested during the twelve (12) month period occurring immediately after the Termination Date shall accelerate and become immediately vested on the Termination Date, unless the applicable equity agreement provides for more favorable vesting treatment.  All other unvested restricted stock, restricted units and performance units held by Executive as of the Termination Date shall be forfeited as of the Termination Date.  

(e)Annual Incentive Bonus.  In lieu of a bonus under the Global Bonus Program for the Company Fiscal Year 2014, the Company will pay Executive a lump sum in the amount of $71, 330.80 minus any applicable deductions or withholdings or other reductions required by applicable law.  Executive hereby waives any rights to any further payment under the Global Bonus Program. 

(f)Subsidized COBRA Premium.  If Executive timely elects COBRA continuation coverage then, during the Severance Period, Executive will be responsible for paying only the employee portion of the applicable premium under the respective plan(s), at the same rate and at the same time as such employee contributions are paid by similarly-situated active Company employees.  

(g)Outplacement Services.  The Company shall pay the cost of outplacement services for the Executive at the outplacement agency the Company regularly uses for such purpose for a period of twelve (12) months and at the level of services offered to similarly-situated Company employees.  

(h)Waiver of Reimbursement of Relocation Expenses.  The Company shall waive its rights to any reimbursement of relocation expenses which the Company has paid in connection with Executive’s relocation to Saint Louis, Missouri.  

(i)Deductions for Amounts Owed to Company.  With respect to any amounts paid pursuant to this Agreement that are not subject to Internal Revenue Code Section 409A, the Company reserves the right to make deductions in accordance with applicable law for any monies owed to the Company by Executive and, by signing this Agreement, Executive expressly authorizes such deductions.  Such amounts owed include, but are not limited to, the value of any Company property Executive has lost, damaged or retained in Executive’s possession, amounts owed under any (i) computer loan program, (ii) sign-on bonus arrangement, (iii) tuition reimbursement program, (iv) visa expense reimbursement program, or (v) program or loan which provides for Executive’s reimbursement of amounts to the Company, draws or other funds advanced to Executive which were not yet earned, or any other overpayment of compensation or benefits to Executive, in any form.  Such deductions can be made to the extent permitted by applicable law from any amounts owed to Executive including, but not limited to, base salary, commission, bonus, salary continuation payments made pursuant to this Agreement, vacation pay, or expense reimbursement.  Any amounts Executive still owes after such offset must be paid within thirty (30) days of the Termination Date.  With respect to any amounts paid pursuant to this Agreement that are subject to Code Section 409A, the Company reserves the right to make deductions in accordance with applicable law for any monies owed to the Company by Executive (as described above); provided, however, such deductions cannot exceed $5,000 in the aggregate in any Company fiscal year.

(j)No Further Benefits.  Except as provided in this Agreement or as required by the terms of a Company sponsored employee benefit plan in which Executive is participating on the Termination Date, no payment, compensation, leave time, insurance or other benefits will be furnished or paid to Executive.  Executive understands the Company may change payroll dates, schedules or amounts payable on such payroll dates, insurance carriers or employee benefit plans or otherwise modify its payroll or employee benefit plans for its active employees and, to the extent Executive is receiving salary continuation payments on payroll dates or is entitled to any such coverage or benefit after the Termination Date, those changes will be applied to Executive as well and in a manner consistent with applicable law.  Except as specifically provided for in this Agreement or the terms of the applicable employee benefit plan, as of the Termination Date, Executive will cease to be eligible to participate under, or be covered by, any compensation or employee benefit plan and has no rights under any of those plans.

3.Release of All Claims.

(a)Executive’s Release of All Claims.    Executive, for and in consideration of the commitments of the Company, including those set forth in the section entitled “Consideration to Executive for Signing This Agreement,” and intending to be legally bound, does hereby REMISE, RELEASE AND FOREVER DISCHARGE the Company, its affiliates, subsidiaries and parents, and its officers, directors, employees, and agents, and its and their respective successors and assigns, heirs, executors, trustees, fiduciaries and administrators (collectively, “Releasees”) from all causes of action, suits, debts, claims and demands whatsoever in law or in equity, which Executive ever had, now has, or hereafter may have, whether known or unknown, or which Executive heirs, executors, or administrators may have, by reason of any matter, cause or thing whatsoever, from the beginning of Executive’s employment to the date Executive signs this Agreement, and particularly, but without limitation of the foregoing general terms, any claims arising from, or relating in any way to, Executive’s employment relationship with Company, the Retention Agreement, the terms and conditions of the employment relationship, and the termination of the employment 

relationship, including, but not limited to, any claims arising under the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, Title VII of The Civil Rights Act of 1964, Sections 1981 and 1983 of the Civil Rights Act of 1866, the Americans with Disabilities Act, the Employee Retirement Income Security Act of 1974, the Workers Adjustment Retraining Notification Act, the Family and Medical Leave Act of 1993, the Genetic Information Non-Discrimination Act of 2008, the Fair Credit Reporting Act, the Equal Pay Act, the Rehabilitation Act of 1973, the Uniformed Services Employment and Reemployment Rights Act,  the National Labor Relations Act, the False Claims Act, the Missouri Human Rights Act (which prohibits employment discrimination based on race, religion, color, ancestry, national origin, age, sex or disability), the Missouri Smokers’ Rights Law (which prohibits bias against employees for using lawful tobacco products during non-working hours while off the employer’s premises), Section 287.780 of Vernon’s Annotated Missouri Statutes (which prohibits discrimination or retaliation against employees for exercising rights under the workers compensation laws), Section 290.140 of Vernon’s Annotated Missouri Statutes (which provides for service letters), and any other claims under any federal, state or local common law, statutory, or regulatory provision, now or hereafter recognized, and any claims for attorneys’ fees and costs.  Executive specifically acknowledges that during Executive’s employment, (i) Executive was provided notice of all rights permitted under the Family and Medical Leave Act of 1993 (“FMLA”), understood those rights, was allowed to take all leave and afforded all other rights to which Executive is entitled under the FMLA, (ii) the Company has not in any way interfered with, restrained or denied Executive’s exercise of (or attempt to exercise) any FMLA rights, nor terminated or otherwise discriminated against Executive for exercising (or attempting to exercise) any such rights, and (iii) Executive was not treated differently or in any way discriminated against because of Executive’s age.  This Agreement is effective without regard to the legal nature of the claims raised and without regard to whether any such claims are based upon tort, equity, implied or express contract or discrimination of any sort.  Nothing in this Agreement shall be interpreted to require Executive to release any claims that cannot lawfully be released.

(b)Executive’s Representations.  To the fullest extent permitted by law, and subject to the provisions of the section entitled “Permissible Disclosures,” Executive represents and affirms (i) Executive has not filed or caused to be filed on Executive’s behalf any claim for relief against the Company or any Releasee and, to the best of Executive’s knowledge and belief, no outstanding claims for relief have been filed or asserted against the Company or any Releasee on Executive’s behalf, (ii) Executive has no knowledge of any improper, unethical or illegal conduct or activities Executive has not already reported to a human resources representative, to any member of the Company’s legal or compliance departments, or to the ethics hotline, and (iii)  Executive will not file, charge, claim, sue or cause or permit to be filed, charged or claimed, any civil action, suit or legal proceeding seeking equitable or monetary relief (including damages, injunctive, declaratory, monetary or other relief) for Executive involving any matter released in this Agreement.  Furthermore, Executive will withdraw with prejudice any such lawsuit or other legal action that may already be pending.  In the event suit is filed in breach of this covenant not to sue, it is expressly understood and agreed this covenant shall constitute a complete defense to any such suit.  In the event any Releasee is required to institute litigation to enforce the terms of this subsection, Releasees shall be entitled to recover reasonable costs and attorneys’ fees incurred in such enforcement.  Executive further agrees and covenants that should any person, organization, or other entity file, charge, claim, sue, or cause or permit to be filed any civil action, suit or legal proceeding involving any matter occurring at any time in the past, Executive will not seek or accept personal equitable or monetary relief in such civil action, suit or legal proceeding.  Although this Agreement does not preclude Executive from filing a charge of discrimination with the Equal Employment Opportunity Commission or related state agency or from participating in an investigation by such agency, Executive promises never to seek or accept any damages, remedies, or other relief for Executive personally (any right to which is hereby waived) with respect to any claim purportedly released by this Agreement.

(c)No Unresolved Claims.  This Agreement has been entered into with the understanding there are no unresolved claims of any nature which Executive has against the Company.  Executive acknowledges and agrees, except as specified in the section entitled “Consideration to Executive for Signing This Agreement,” all compensation, benefits, and other obligations due Executive by the Company, whether by contract or by law, have been paid or otherwise satisfied in full or have been provided for in this Agreement.  Executive further agrees the representations and understandings set forth in this Agreement have been relied upon by the Company and constitute consideration for the Company’s execution of this Agreement.

4.Restrictions.  Any agreement signed by Executive at the time of hire or during employment regarding non-disclosure; trade secrets; confidential or proprietary information; disclosure or ownership of inventions, methods, processes or improvements; non-solicitation; or non-competition, including the Non-Competition, Non-Solicitation, and Confidentiality Agreement by and between Executive and the Company which Executive signed on January 4, 2013, shall continue in full force and effect.

5.Continued Cooperation.  Executive acknowledges the Company may need to consult with Executive from time to time on a reasonable basis after the Termination Date on matters Executive had worked on prior to the Termination Date.  Executive agrees to continue to cooperate with the Company and to provide any such information as is reasonably requested by the Company.  The Company will reimburse Executive for any reasonable pre-approved expenses incurred in providing this cooperation and will not unreasonably interfere with any future employment of Executive in these requests.

6.Rehire.  Executive agrees and recognizes Executive has permanently and irrevocably severed Executive’s employment relationship with the Company, Executive shall not seek employment or seek to provide services as an employee, consultant, independent contractor or otherwise with the Company or any affiliated entity at any time in the future, and the Company has no obligation to employ, or retain the services of, Executive in the future.

7.Non-Disparagement.  Subject to the provisions of the section entitled “Permissible Disclosures,” Executive agrees Executive will not disparage or subvert the Company, or make any statement reflecting negatively on the Company, its affiliated corporations or entities, or any of their officers, directors, employees, agents or representatives, including, but not limited to, any matters relating to the operation or management of the Company, Executive’s employment and the termination of Executive’s employment, irrespective of the truthfulness or falsity of such statement.  It is the Company’s current reference policy to confirm only the Executive’s dates of employment, job title and most recent salary upon receipt of a reference request.

8.Understanding of Consideration.  Executive understands and agrees the payments, benefits and agreements provided in this Agreement, including those set forth in the section entitled “Consideration to Executive for Signing This Agreement,” are being provided to Executive in consideration for Executive’s acceptance and execution of, and in reliance upon Executive’s representations in, this Agreement and they are greater than the payments, benefits and agreements, if any, to which the Executive would have received if Executive had not executed this Agreement.

9.Satisfaction of Company Obligations.  Executive acknowledges and agrees the Company previously has satisfied any and all obligations owed to Executive under any employment agreement or offer letter Executive has with the Company and, further, this Agreement fully supersedes any and all prior agreements or understandings including but not limited to the Retention Agreement, whether written or oral, between the parties, regarding the subject matter of this Agreement.  Executive acknowledges, except as set forth expressly herein, neither the Company, the Releasees, nor their agents or attorneys have made any promise, representation or warranty whatsoever, either express or implied, or written or oral.

10.Confidentiality.  Subject to the provisions of the section entitled “Permissible Disclosures,” Executive agrees not to disclose the terms of this Agreement to anyone, except a spouse, attorney, or, as necessary, a tax or financial advisor.  It is expressly understood any violation of the confidentiality obligation imposed hereunder constitutes a material breach of this Agreement.

11.Company Property.

(a)Company Records.  Executive represents, as of the Termination Date, Executive shall not have in Executive’s possession any records or business documents, whether on computer or hard copy, or other materials (including but not limited to computer disks and tapes, computer programs, files and software, correspondence, files, customer lists, technical information, customer information, pricing information, business strategies and plans, sales records and all copies thereof) (collectively, the “Corporate Records”) provided by the Company and/or its predecessors, subsidiaries or affiliates or obtained as a result of Executive’s employment with the Company and/or its predecessors, subsidiaries or affiliates, or created by Executive while employed by or rendering services to the Company and/or its predecessors, subsidiaries or affiliates.  Executive acknowledges all such Corporate Records are the property of the Company.

(b)Company Property.  On or before the Termination Date, Executive is required to return all company property to Monica Andersen, Vice President Human Resources.  Company property includes, but is not limited to, building I.D. and name tags, office keys and company car keys, Executive’s Company computer (including laptop), cell phone or other handheld communication device (e.g., BlackBerry, iPhone or iPad), samples, cases, or brochures Executive has acquired by virtue of Executive’s employment.  As of the Termination Date, the Company will make arrangements to remove, terminate or transfer any and all business communication lines including network access, cellular phone, fax line and other business numbers.

12.Permissible Disclosures.  Nothing in this Agreement shall prohibit or restrict Executive from: (i) making any disclosure of information required by law, (ii) providing information to, or testifying or otherwise assisting in any investigation or proceeding brought by, any federal or state regulatory or law enforcement agency or legislative body, any self-regulatory organization, or the Company’s designated legal, compliance or human resources personnel, or (iii) filing, testifying, participating in or otherwise assisting in a proceeding relating to an alleged violation of any federal, state or municipal law relating to fraud, or any rule or regulation of the Securities and Exchange Commission or any self-regulatory organization.

13.Non-Admission.  The Company and Executive mutually agree and acknowledge the provision of benefits by the Company pursuant to this Agreement and the settlement and termination of any asserted or unasserted claims against the Releasees are not and shall not be construed to be an admission of any violation of any federal, state or local statute or regulation, or of any duty owed by any of the Releasees to Executive.

14.Breach.  Executive agrees and recognizes should Executive breach any of the obligations or covenants set forth in this Agreement, the Company will have no further obligation to provide Executive with the consideration set forth herein, and will have the right to seek repayment of all consideration paid up to the time of any such breach.  Further, Executive acknowledges in the event of a breach of this Agreement, Releasees may seek any and all appropriate relief for any such breach, including equitable relief and/or money damages, attorney’s fees and costs.  If it is discovered at any time Executive engaged in behavior during employment that would have justified termination for cause, any consideration payable to Executive under this Agreement shall immediately cease, Executive’s annual incentive or other bonus payment(s) may be withheld in whole or in part, and Executive shall be required to return any consideration paid under this Agreement.  The Company may withhold paying any further consideration pending resolution of an inquiry that could lead to a finding resulting in cause.  For purposes of this Agreement, “cause” shall mean an Executive’s (i) violation of any fiduciary duty owed to the Company, (ii) conviction of a felony or misdemeanor, (iii) dishonesty, (iv) theft, (v) violation of Company rules or policy, or (vi) other egregious conduct that has or that could have a serious and detrimental impact on the Company or any of its affiliates or subsidiaries or any of their employees.

15.Injunctive Relief.  Executive further agrees the Company shall be entitled to preliminary and permanent injunctive relief, without the necessity of proving actual damages, as well as to an equitable accounting of all earnings, profits and other benefits relating to or arising out of any violations of this Agreement, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled.  Executive irrevocably and unconditionally (i) agrees any suit, action or other legal proceeding relating to or arising out of this Agreement, including without limitation, any action commenced by the Company for preliminary and permanent injunctive relief or other equitable relief, may be brought in the State of Missouri, (ii) consents to the non-exclusive jurisdiction of any such court in any such suit, action or proceeding, and (iii) waives any objection which Executive may have to the laying of venue of any such suit, action or proceeding in any such court.  Executive also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other papers by personal service or by registered or certified mail, return receipt requested, or by overnight express courier service, addressed to Executive at the home address which the Company has on file for Executive at the time such mailing occurs.

16.Choice of Law.  The Company’s primary place of business is in the State of Missouri.  Therefore, this Agreement and the obligations of the parties hereunder shall be construed, interpreted and enforced in accordance with the laws of the State of Missouri, without giving effect to any conflict of law principles that would result in the application of any law other than the law of the State of Missouri.

17.Survival of Provisions.  The obligations contained in any section that contains obligations to be performed following the termination of Executive’s employment with the Company or any affiliate or subsidiary shall survive such termination and shall be fully enforceable thereafter.

18.Savings Clause.  If any term contained in this Agreement is found by a court of competent jurisdiction to be unenforceable or invalid to any extent, such finding will not affect the validity or enforceability of any other term or provision of this Agreement.

19.Binding Effect; Assignment.  The rights and obligations of this Agreement shall bind and inure to the benefit of any successor of the Company by reorganization, merger or consolidation, or any assignee of all or substantially all of the Company’s business.  The Company may assign its rights and obligations under this Agreement to any of its subsidiaries or affiliates without Executive’s consent, but shall remain liable for any payments provided 

hereunder that are not timely made by any such assignee.  Executive’s rights or obligations under this Agreement may not be assigned by Executive.

20.Section 409A Compliance.  To the extent applicable, this Agreement will be interpreted in accordance with Internal Revenue Code Section 409A and the regulations and other interpretive guidance issued thereunder including, without limitation, any such regulations or other guidance that may be issued after the date this Agreement is executed.  Notwithstanding any other provision of this Agreement, if the Company determines any provision herein is or may be subject to Code Section 409A, the provisions of Section 5.03 of the Plan apply and the Company may adopt such amendments or modify payments made hereunder or take any other action or actions the Company determines is necessary or appropriate to (i) exempt payments made hereunder from the application of Code Section 409A or (ii) comply with the requirements of Code Section 409A.  Notwithstanding any other provision of this Agreement, if the period for consideration and revocation of this Agreement spans two tax years, then any payments hereunder which are subject to Code Section 409A shall be delayed until the later of (x) the end of the applicable revocation period, or (y) the first regularly scheduled Company payroll date in the second tax year.

21.Certification and Acknowledgment.  Executive certifies and acknowledges as follows:

(a)Executive has read the terms of this Agreement, and Executive understands its terms and effects, including the fact that Executive has agreed to RELEASE AND FOREVER DISCHARGE the Company and each and every one of its affiliated entities from any legal action arising out of Executive’s employment relationship with the Company and the termination of that employment relationship;

(b)Executive has signed this Agreement voluntarily and knowingly in exchange for the consideration described herein, which Executive acknowledges is adequate and sufficient to Executive and which Executive acknowledges is in addition to any other benefits to which Executive is otherwise entitled;

(c)Executive has been and is hereby advised in writing to consult with an attorney prior to signing this Agreement;

(d)Executive does not waive rights or claims that may arise after the date this Agreement is executed;

(e)The Company has provided Executive with a period of at least twenty-one (21) days within which to consider this Agreement, and Executive has signed on the date indicated below after concluding this Agreement is satisfactory to Executive; and

(f)Executive acknowledges this Agreement may be revoked by Executive within seven (7) days after Executive’s execution and this Agreement shall not become effective until the expiration of such seven (7) day revocation period.  Any revocation must be submitted, in writing, to the Company, and state, “I hereby revoke my acceptance of our Agreement.”  The revocation must be personally delivered to Monica Andersen or a designee, or mailed to Monica Andersen, Vice President Human Resources, Mallinckrodt, 675 McDonnell Boulevard, Hazelwood, MO 63042 and postmarked within seven (7) calendar days of Executive’s execution of this Agreement.  In the event of a timely revocation by Executive, this Agreement will be deemed null and void and the Company will have no obligations hereunder.

Intending to be legally bound hereby, Executive and the Company (by its duly authorized agent) hereby execute the foregoing Separation of Employment Agreement and General Release.

EXECUTIVE

	
			
	/s/ Stephen Merrick
	 
	July 3, 2014

	Signature
	 
	Date

	 
	 
	 

COMPANY

	
			
	/s/ Ian J. Watkins
	 
	July 8, 2014

	Signature
	 
	Date

	 
	 
	 

	Name: Ian J. Watkins
	 
	 

	 
	 
	 

	Title: SVP Human ResourcesExhibit 10.1

 

Execution Version

 

FIRST AMENDED AND RESTATED SUPPORT
AGREEMENT

 

This FIRST AMENDED
AND RESTATED SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of August 6, 2014, by and among
Healthy Harmony Holdings, L.P., a Cayman Islands limited partnership (“Parent”), TPG Asia VI, L.P., a Cayman
Islands limited partnership (the “Sponsor”) (solely for the purpose of Sections 3(e), 9(a), 9(c), 9(d), 9(e),
9(f), 10 and 17), and the stockholders of Chindex International, Inc., a Delaware corporation (the “Company”),
listed on Schedule A-1 hereto (each, together with his, her or its heirs, beneficiaries, executors, successors and permitted
assigns, a “Stockholder” and, collectively the “Stockholders”, and together with Parent and
Sponsor, the “parties”).

 

WITNESSETH:

 

WHEREAS, on February
17, 2014, Parent, Healthy Harmony Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger
Sub”), and the Company entered into an Agreement and Plan of Merger, which was subsequently amended and restated on April
18, 2014 (as it may be further amended, supplemented or otherwise modified from time to time, the “Merger Agreement”),
which provides for, among other things, the merger of Merger Sub with and into the Company (the “Merger”) with
the Company continuing as the surviving corporation of the Merger;

 

WHEREAS, as of the
date hereof each Stockholder is the beneficial owner (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended
(the “Exchange Act”)) of the number of shares of common stock, par value $0.01 per share (including shares designated
as Class B common stock) (the “Shares”) set forth opposite the name of such Stockholder on Schedule A-1
hereto;

 

WHEREAS, in connection
with the consummation of the transactions contemplated by the Merger Agreement, each Stockholder set out in Schedule A-2 hereto
(a “Rollover Stockholder”) desires to contribute the Shares set forth opposite the name of such Stockholder
on Schedule A-2 hereto to Parent in exchange for such number of newly issued limited partnership interests of Parent (the
“Parent Interests”) set forth opposite the name of such Stockholder on Schedule A-2 hereto;

 

WHEREAS, the Board
of Directors of the Company has, prior to the execution of this Agreement, approved, for purposes of Section 203 of the Delaware
General Corporation Law (the “DGCL”), Parent, Merger Sub and the other Affiliates of Parent each becoming an
“interested stockholder” (as defined in Section 203 of the DGCL);

 

WHEREAS, as a condition
and inducement to the willingness of Parent and Merger Sub to enter into the Merger Agreement, each Stockholder (in his, her or
its capacity as such) and the Sponsor entered into a Support Agreement on February 17, 2014 (the “Original Support Agreement”);

 

WHEREAS, Significant
Stockholder (as defined below) entered into a stock pledge agreement with Parent and Sponsor in respect of the Shares owned by
Significant Stockholder on August 6, 2014 (the “Stock Pledge Agreement”);

 

WHEREAS, each party
to the Original Support Agreement desires to amend the Original Support Agreement to (a) replace Schedule A-2 to the Original
Support Agreement with Schedule A-2 hereto, such that each Rollover Stockholder shall contribute the number of Shares set
forth on Schedule A-2 hereto in exchange for the number of newly issued Parent Interests set forth opposite such Rollover
Stockholder’s name on Schedule A-2 hereto, and (b) amend certain provisions of the Original Support Agreement; and

 

    	 

    	 

    

 

WHEREAS, the Stockholders
and the Sponsor acknowledge that Parent, the Company and Merger Sub entered into the Merger Agreement in reliance on the representations,
warranties, covenants and other agreements of the Stockholders and the Sponsor set forth in the Original Support Agreement.

 

NOW, THEREFORE, in
consideration of the foregoing and the mutual covenants and agreements set forth herein and in the Merger Agreement, and intending
to be legally bound hereby, the parties hereto agree as follows:

 

1.           Certain
Definitions. All capitalized terms that are used but not defined herein shall have the respective meanings ascribed to them
in the Merger Agreement. For all purposes of and under this Agreement, the following terms shall have the following respective
meanings:

 

(a)          “Advisor”
shall have the meaning set forth in Section 10(a) hereof.

 

(b)          “Agreement”
shall have the meaning set forth in the preamble.

 

(c)          “Breaching
Party” shall have the meaning set forth in Section 10(c) hereof.

 

(d)          “Company”
shall have the meaning set forth in the preamble.

 

(e)          “Contribution
Closing” shall have the meaning set forth in Section 3(c) hereof.

 

(f)          “DGCL”
shall have the meaning set forth in the recitals.

 

(g)          “Encumbrance”
shall have the meaning set forth in Section 7(a) hereof.

 

(h)          “Exchange
Act” shall have the meaning set forth in the recitals.

 

(i)          “Expiration
Date” shall mean the earliest to occur of (i) solely with respect to the Stockholder’s obligations under Section
2 hereof, the Effective Time, (ii) the date and time the Merger Agreement is terminated in accordance with its terms and provisions,
and (iii) the effectiveness of a mutual written agreement of the parties hereto to terminate this Agreement.

 

(j)          “Letters
of Commitment” shall have the meaning set forth in Section 9(b) hereof.

 

(k)          “Management
Stockholders” shall mean Roberta Lipson, Elyse Silverberg and Lawrence Pemble.

 

(l)          “Merger”
shall have the meaning set forth in the recitals.

 

(m)          “Merger
Agreement” shall have the meaning set forth in the recitals.

 

(n)          “Merger
Sub” shall have the meaning set forth in the recitals.

 

(o)          “parties”
shall have the meaning set forth in the preamble.

 

(p)          “Parent”
shall have the meaning set forth in the preamble.

 

(q)          “Parent
Interests” shall have the meaning set forth in the recitals.

 

(r)          “Proxy”
shall have the meaning set forth in Section 2(b) hereof.

 

    	- 2 -

    	 

    

 

(s)          “Rollover
Stockholder” shall have the meaning set forth in the recitals.

 

(t)          “Securities
Act” shall have the meaning set forth in Section 7(a) hereof.

 

(u)          “Share
Documents” shall have the meaning set forth in Section 3(d) hereof.

 

(v)         “Shareholders
Agreement” shall have the meaning set forth in Section 9(a) hereof.

 

(w)          “Significant
Stockholder” shall have the meaning set forth in Section 9(b) hereof.

 

(x)          “Significant
Stockholder Equity Commitment Letter” means the amended and restated letter agreement dated April 18, 2014 between Significant
Stockholder and Parent.

 

(y)          “Significant
Stockholder Letter of Commitment” shall have the meaning set forth in Section 9(b) hereof.

 

(z)          “Significant
Stockholder Parent” shall have the meaning set forth in Section 9(b) hereof.

 

(aa)         “Significant
Stockholder Parent’s Meeting” shall have the meaning set forth in Section 9(b) hereof.

 

(bb)         “Significant
Stockholder Transactions” shall have the meaning set forth in Section 9(b) hereof.

 

(cc)         “Sponsor”
shall have the meaning set forth in the preamble.

 

(dd)         “Stock
Pledge Agreement” shall have the meaning set forth in the preamble.

 

(ee)         “Stockholder”
shall have the meaning set forth in the preamble.

 

(ff)         “Stockholder
Agreement” shall have the meaning set forth in Section 2(g) hereof.

 

(gg)         “Subscription
Agreement” shall have the meaning set forth in Section 9(d) hereof.

 

(hh)         “Term
Sheet” shall have the meaning set forth in Section 9(a) hereof.

 

(ii)         “Transfer”
A Person shall be deemed to have effected a “Transfer” of a Share if such Person directly or indirectly (i)
sells, pledges, encumbers, assigns, grants an option with respect to, transfers, tenders or otherwise disposes of such Share or
any interest in such Share in any manner, for or without consideration, or (ii) enters into an agreement or commitment providing
for the sale of, pledge of, encumbrance of, assignment of, grant of an option with respect to, transfer of, tender of or other
disposition of such Share or any interest therein in any manner, for or without consideration, provided, that, for the avoidance
of doubt, “Transfer” does not include granting a proxy or voting or consent instructions with respect to any matter
other than those specified in clauses (x) and (y) of Section 2(a)(ii).

 

(jj)         “Voting
Obligation” shall have the meaning set forth in Section 2(g) hereof.

 

2.           Agreement
to Vote Shares; Irrevocable Proxy.

 

(a)         At
every meeting of the stockholders of the Company, and at every adjournment or postponement thereof, and on every action or approval
by written consent of the stockholders of the

 

    	- 3 -

    	 

    

 

 Company, each Stockholder (in such Stockholder’s capacity as such), to the
extent not so voted by the Person(s) appointed under a Proxy, shall, or shall cause the holder of record on any applicable record
date to, (i) in the case of a meeting, appear at such meeting or otherwise cause the Shares to be counted as present for purposes
of calculating a quorum and (ii) vote all Shares as to which such Stockholder has sole or shared voting power and is entitled to
vote or act by written consent:

 

(x)          in
favor of (A) the approval and adoption of the Merger Agreement, the approval of the Merger and the other transactions contemplated
by the Merger Agreement and any other matter that must be approved by the stockholders of the Company in order for the transactions
contemplated by the Merger Agreement to be consummated and (B) any adjournment, recess, delay or postponement recommended
by the Company (and not publicly opposed by Parent) with respect to any stockholder meeting with respect to the Merger Agreement
and the Merger; and

 

(y)          against
any of the following actions and matters (other than those in furtherance of the Merger and the Merger Agreement): (A) any Alternative
Proposal with respect to the Company, (B) any adjournment, recess, delay or postponement of any stockholder meeting with respect
to the Merger Agreement and the Merger publicly opposed by Parent, or (C) any other action or matter that (1) would reasonably
be expected to materially impede, interfere with, delay, postpone, discourage or adversely affect the timely consummation of the
Merger or any other transactions contemplated by the Merger Agreement or (2) would reasonably be expected to result in a material
breach of any covenant, representation or warranty, or any other obligation or agreement of the Company under the Merger Agreement.

 

Each Stockholder shall retain at all times
the right to vote his, her or its Shares in his, her or its sole discretion and without any other limitation on those matters other
than those set forth in clauses (x) and (y) above that are at any time or from time to time presented for consideration to the
Company’s stockholders. For the avoidance of doubt, clauses (x) and (y) of this Section 2(a)(ii) shall not apply
to votes, if any, solely on the election or removal of directors as recommended by the Company Board (provided such recommendation
is not in violation of the terms of the Merger Agreement).

 

(b)          In
furtherance of the agreements herein and concurrently with the execution of the Original Support Agreement, each Stockholder has
delivered (or, in the case of Significant Stockholder, within five Business Days after the receipt of the Requisite Significant
Stockholder Stockholder Approval, shall deliver) to Parent a proxy in the form attached hereto as Exhibit A (each such proxy,
a “Proxy”), which shall be irrevocable to the fullest extent permissible by law, with respect to all of such
Stockholder’s Shares.

 

(c)          Each
Stockholder has taken all action necessary to revoke any previously granted proxies in respect of his, her or its Shares and no
subsequent proxies in respect of any matters set forth in Section 2(a) will be given during the term of this Agreement.

 

(d)          Each
Stockholder hereby acknowledges that the Proxy is (or, in the case of Significant Stockholder, will be) given in connection with,
and in consideration of, the execution of the Merger Agreement by Parent, and that such irrevocable proxy is (or, in the case of
Significant Stockholder, will be) given to secure the performance of the duties of such Stockholder under this Agreement. Each
Stockholder hereby further acknowledges that the Proxy is (or, in the case of Significant Stockholder, will be) coupled with an
interest sufficient in law to support an irrevocable power and may under no circumstances be revoked. Such Proxy was executed by
each Stockholder on the date of the Original Support Agreement (or, in the case of Significant Stockholder, shall be executed within
five Business Days of receipt of the Requisite Significant Stockholder Stockholder Approval) and is intended to be irrevocable
in accordance with the provisions of Section 212 of the DGCL until the 

 

    	- 4 -

    	 

    

 

termination of this Agreement in accordance with its terms.
The vote of Parent (or its designee) as proxyholder shall control in any conflict between the vote by such proxyholder of such
Stockholder’s Shares and a purported vote by such Stockholder of such Stockholder’s Shares.

 

(e)          Subject
to the proviso to Section 12 below, each Stockholder hereby agrees that it shall not, and shall cause each of its controlled
Affiliates not to, become a member of a “group” (as that term is used in Section 13(d) of the Exchange Act) (other
than as a result of entering into this Agreement) with respect to any Shares or any other securities of the Company for the purpose
of opposing the Merger Agreement, the Merger or any other transactions contemplated by the Merger Agreement, or soliciting, initiating,
or knowingly encouraging or facilitating the submission of, any Alternative Proposal.

 

(f)          The
Stockholder shall not enter into any agreement with any Person to vote or give instructions in any manner inconsistent with the
terms of this Section 2.

 

(g)          For
the avoidance of doubt, in no event shall the compliance by Significant Stockholder of its obligations under Sections 2.1 and 2.2
of the Stockholder Agreement dated June 14, 2010 among the Company, Significant Stockholder and Significant Stockholder Parent
(the “Stockholder Agreement”) solely with respect to any matter upon which a vote, consent or other approval
is sought from the stockholders of the Company for the election or removal of directors of the Company (or relating to procedures
applicable to the election of directors) (the “Voting Obligation”) be deemed as a breach of the provisions of
this Section 2.

 

3.           Contribution
and Rollover of Shares.

 

(a)          Contribution
of Shares. Subject to the conditions set forth herein and in the case of Significant Stockholder, the provisions of the Stock
Pledge Agreement, at the Contribution Closing (as defined below), each Rollover Stockholder shall contribute, assign, transfer
and deliver to Parent the Shares held by him, her or it in the amount set forth opposite such Stockholder’s name on Schedule
A-2 hereto, free and clear of any Encumbrance. The contribution of such Shares to Parent is intended by the Rollover Stockholders
to be treated as a tax-free contribution under section 721 of the Code.

 

(b)          Issuance
of Parent Interests. As consideration for the contribution, assignment, transfer and delivery of the Shares to Parent pursuant
to Section 3(a), at the Contribution Closing (as defined below), Parent shall issue Parent Interests in the name of each
Rollover Stockholder (or, if designated by such Rollover Stockholder in writing, in the name of an Affiliate of such Rollover Stockholder)
in the amount set forth opposite such Rollover Stockholder’s name on Schedule A-2. Each Rollover Stockholder hereby
acknowledges and agrees that (i) delivery of such Parent Interests shall constitute complete satisfaction of all obligations towards
or sums due to such Rollover Stockholder by Parent with respect to the applicable Shares being contributed, assigned, transferred
or delivered, and (b) on receipt of such Parent Interests, such Rollover Stockholder shall have no right to any Merger Consideration
with respect to the Shares contributed to Parent by such Rollover Stockholder.

 

(c)          Closing.
Subject to the satisfaction in full (or waiver) of all of the conditions set forth in Sections 7.1 and 7.2 of the Merger Agreement
(other than conditions that by their nature are to be satisfied at the Closing), the closing of the contribution and exchange contemplated
hereby (the “Contribution Closing”) shall take place on a date mutually agreed by the parties not later than
one (1) Business Day prior to the Closing.

 

(d)          Deposit
of Shares. No later than five (5) Business Days prior to the date of the Contribution Closing, the Rollover Stockholders (other
than Significant Stockholder) and any agent of such Rollover Stockholders holding certificates evidencing any Shares shall deliver
or cause to be

  

    	- 5 -

    	 

    

 

delivered to Parent
all certificates representing Shares as set forth on Schedule A-2 hereto in such Persons’ possession, (i) duly endorsed
for transfer or (ii) with executed stock powers, both reasonably acceptable in form to Parent and sufficient to transfer such
shares to Parent, for disposition in accordance with the terms of this Agreement (the “Share Documents”). The
Share Documents shall be held by Parent or any agent authorized by Parent until the Contribution Closing.

 

(e)          Notice
of Transfer. No later than five (5) Business Days prior to the date of the Contribution Closing, Significant Stockholder shall
deliver a written notice to Sponsor instructing Sponsor, as collateral agent under the Stock Pledge Agreement, to transfer the
Pledged Shares (as defined in the Stock Pledge Agreement), including the executed instrument of transfers in blank, to Parent on
or prior to the Contribution Closing. Upon receipt of such instruction, Sponsor shall use its reasonable best efforts to complete
the transfer of the Pledge Shares to Parent according to the instruction set forth in such notice. Significant Stockholder hereby
irrevocably authorizes Parent to date and fill in the executed instruments of transfer in blank to transfer the Pledged Shares
to Parent, for disposition in accordance with the terms of this Agreement. Delivery of the aforementioned notice shall be deemed
to constitute full performance of Significant Stockholder’s obligations under Section 3(a) and shall constitute a
complete discharge of such obligations of Significant Stockholder.

 

(f)          Irrevocable
election. The execution of this Agreement by the Rollover Stockholders evidences, subject to Sections 12 and
14 of this Agreement and, in the case of Significant Stockholder, the receipt of the Requisite Significant Stockholder Stockholder
Approval, the irrevocable election and agreement by the Rollover Stockholders to contribute their respective Shares as set forth
in Schedule A-2 hereto in exchange for Parent Interests at the Contribution Closing on the terms and conditions set forth
herein.

 

4.           Transfer
of Shares; New Shares.

 

(a)          In
furtherance of the foregoing covenants, each Stockholder covenants and agrees, severally and not jointly, that from the date of
the Original Support Agreement until the Expiration Date of this Agreement, such Stockholder shall not (i) Transfer (or cause or
permit the Transfer of) any Shares (or enter into any Contract relating to the Transfer of any Shares) or any right, title or interest
thereto or therein, other than, with respect to Significant Stockholder, the execution and performance of the Stock Pledge Agreement,
(ii) deposit (or cause or permit the deposit of) any Shares in a voting trust or grant any proxy or enter into any voting agreement
or similar agreement with respect to any of the Shares or take any similar action in contravention of the obligations of the Stockholder
under this Agreement, other than, with respect to Significant Stockholder, its compliance with the Voting Obligation or the execution
and performance of the Stock Pledge Agreement, (iii) knowingly take any action that would make any representation or warranty of
such Stockholder set forth in this Agreement untrue or incorrect or have the effect of preventing, disabling, or delaying such
Stockholder from performing any of his, her, or its obligations under this Agreement, or (iv) agree (whether or not in writing)
to take any of the actions referred to in the foregoing clauses (i) through (iii); provided, however, that for the
avoidance of doubt, (x) each Stockholder may engage in good faith discussions and negotiations regarding an Alternative Proposal
if and only to the extent the Company is permitted pursuant to Section 6.2 of the Merger Agreement to engage in such discussions
and negotiations or as otherwise permitted pursuant to the proviso to Section 12 and (y) Transfers of Shares in connection
with the consummation of any Alternative Proposal shall not be prohibited as long as such Transfer is effected simultaneously with
the occurrence of, or after, the Expiration Date. This Section 4 shall not prohibit a Transfer of the Shares by any
Stockholder to any member of such Stockholder’s immediately family, or to a trust for the benefit of such Stockholder or
any member of such Stockholder’s immediate family, or to an Affiliate of such Stockholder; provided, that a Transfer
referred to in this sentence shall be permitted only if, as a precondition to such Transfer, the transferee agrees in a writing,
reasonably satisfactory in form and 

 

    	- 6 -

    	 

    

 

substance to Parent, to be bound by all of the terms of this Agreement. Any Transfer, or purported
Transfer, of Shares in breach or violation of this Agreement shall be void and of no force.

 

(b)          Each
Stockholder covenants and agrees, severally and not jointly, that such Stockholder shall promptly (and in any event within forty-eight
(48) hours) notify Parent of any new Shares with respect to which beneficial ownership (within the meaning of Rule 13d-3 of the
Exchange Act) is acquired by such Stockholder, including, without limitation, by purchase, as a result of a stock dividend, stock
split, recapitalization, combination, reclassification, exchange or change of such Shares, or upon exercise or conversion of any
securities of the Company, if any, after the date of the Original Support Agreement. Any such Shares shall automatically become
subject to the terms of this Agreement, and Schedule A-1 shall be deemed amended accordingly.

 

5.           Agreement
Not to Exercise Appraisal Rights. Each Stockholder shall not exercise, and hereby irrevocably and unconditionally waives, any
statutory rights (including under Section 262 of the DGCL) to demand appraisal of any Shares that may arise in connection with
the Merger or the Merger Agreement.

 

6.           Directors
and Officers. It is understood that each Stockholder enters into this Agreement solely in such Stockholder’s capacity
as a stockholder of the Company. Notwithstanding any provision of this Agreement to the contrary, nothing in this Agreement shall
be construed as preventing or limiting a Stockholder (in the case of an individual) or a director, officer or employee of a Stockholder
or affiliate of a Stockholder (in the case of an entity), who is a director or officer of the Company, from taking (or omitting
to take) any action in such capacity or fulfilling the obligations of such office, including by performing the obligations required
by the fiduciary obligations of such Stockholder (in the case of an individual) or such director, officer or employee of a Stockholder
or affiliate of a Stockholder (in the case of an entity), in his or her capacity as a director or officer of the Company, in such
person’s sole discretion on any matter. Accordingly, and by way of non-exhaustive example, if a Stockholder is a director
of the Company, nothing in this Agreement shall prohibit or otherwise restrict such Stockholder in his or her capacity as a director
to vote (a) for any Change in Recommendation subject to, and in accordance with, the terms and conditions set forth the Merger
Agreement, (b) to terminate the Merger Agreement pursuant to Section 8.1 of the Merger Agreement or (c) to cause the
Company to sue Parent, Sponsor and Significant Stockholder for breach of any of their respective obligations under this Agreement,
the Merger Agreement, the Equity Commitment Letter and the Guarantee, as applicable. For the avoidance of doubt, nothing in this
Agreement shall modify any of the rights or obligations under the Merger Agreement.

 

7.           Representations
and Warranties of the Stockholders. Each Stockholder hereby represents and warrants to Parent, severally and not jointly, and
solely as to itself and its Shares, as follows:

 

(a)          Ownership.
Except as disclosed in the Stockholders Disclosure Schedule attached hereto, such Stockholder (i) is the sole beneficial owner
of, and has good, valid and marketable title to, the Shares set forth opposite such Stockholder’s name on Schedule A-1
hereto, free and clear of any and all liabilities, liens, claims, security interests, proxies, voting trusts or agreements, options,
rights, understandings or arrangements or any other encumbrances whatsoever on title, transfer, or exercise of any rights of a
stockholder in respect of such Shares (collectively, “Encumbrances”) except for restrictions on Transfer under
the Securities Act of 1933, as amended (the “Securities Act”), other applicable Laws or Encumbrances arising
hereunder and in the case of Significant Stockholder, the Encumbrances set forth in the Stockholder Agreement (subject to the Waiver
Agreement dated February 17, 2014 among the Company, Significant Stockholder and Significant Stockholder Parent, the Waiver Agreement
dated April 18, 2014 among the Company, Significant Stockholder and Significant Stockholder Parent and the Waiver Agreement dated
August 6, 2014 among the Company, Significant

 

    	- 7 -

    	 

    

 

Stockholder and Significant
Stockholder Parent, in each case, as amended, restated or otherwise modified from time to time) and the Stock Pledge Agreement;
(ii) does not own as of the date hereof, of record or beneficially, any shares of capital stock of the Company (or rights
to acquire any such shares) other than (x) Company Options and RSUs, and (y) the Shares set forth on Schedule A-1
hereto; and (iii) has the right to vote, dispose of and exercise and holds power to issue instructions with respect to the matters
set forth in Sections 2(a)(ii)(x) and 2(a)(ii)(y) hereof, sole power to demand appraisal rights and power
to agree to all of the matters set forth in this Agreement with respect to all of such Stockholder’s Shares, with no limitations,
qualifications or restrictions on such rights, subject to applicable federal securities laws and the terms of this Agreement and,
in the case of the Significant Stockholder, its Voting Obligation, the restrictions in Article IV of the Stockholder Agreement
and the Stock Pledge Agreement.

 

(b)          Organization.
If such Stockholder is an entity, such Stockholder is an entity duly organized, validly existing and in good standing under the
Laws of the jurisdiction in which it is incorporated or constituted. If such Stockholder is an individual, such Stockholder is
a resident of the country set forth on Schedule A-1 hereto.

 

(c)          Power;
Binding Agreement. Such Stockholder has the legal capacity and all requisite power and authority to execute and deliver
this Agreement and the Proxy, to perform such Stockholder’s obligations hereunder and to consummate the transactions contemplated
hereby (in case of the Significant Stockholder, subject to the receipt of the Requisite Significant Stockholder Stockholder Approval
with respect to its obligations under Sections 2 and 3). The execution, delivery and performance by such Stockholder
of this Agreement and the Proxy and the consummation by such Stockholder of the transactions contemplated hereby have been duly
authorized and approved by such Stockholder, and no other actions on the part of such Stockholder are necessary to authorize the
execution and delivery by such Stockholder of this Agreement and the consummation by such Stockholder of the transactions contemplated
hereby (in case of the Significant Stockholder, except for the approval of the Significant Stockholder Transactions by stockholders
of Significant Stockholder Parent by ordinary resolutions passed at the Significant Stockholder Parent’s Meeting). This Agreement
has been duly and validly executed and delivered by such Stockholder, and, assuming this Agreement constitutes a valid and binding
obligation of Parent, constitutes a valid and binding obligation of such Stockholder, enforceable against such Stockholder in accordance
with its terms, except that such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium and other similar applicable Laws affecting or relating to creditors’ rights generally and is subject to general
principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or law).

 

(d)          No
Conflicts. None of the execution and delivery by such Stockholder of this Agreement, the performance by such Stockholder
of his, her or its obligations hereunder or the consummation by such Stockholder of the transactions contemplated hereby will (i)
result in a violation or breach of, or constitute (with or without notice or lapse of time or both) a default under, or conflict
with (A) any provisions of the organizational documents of such Stockholder (if such Stockholder is an entity) or (B) any Contract
to which such Stockholder is a party or by which such Stockholder’s Shares are bound, or (ii) except, in the case of Significant
Stockholder, the Parent Required Governmental Approvals, as applicable, violate, or require any consent, approval, or notice under,
any provision of any judgment, order or decree or any Law applicable to such Stockholder or any of such Stockholder’s Shares
(other than filings required pursuant to the Exchange Act or similar Laws).

 

(e)          Absence
of Litigation. There is no Proceeding pending or, to the knowledge of such Stockholder, threatened against such Stockholder
in a writing delivered to such Stockholder that restricts or prohibits (or, if successful, would restrict or prohibit) the performance
by such Stockholder of his, her or its obligations under this Agreement.

 

    	- 8 -

    	 

    

 

(f)          Reliance
by Parent. Such Stockholder has received and reviewed a copy of the Merger Agreement. Such Stockholder understands and acknowledges
that Parent is entering into the Merger Agreement in reliance upon such Stockholder’s execution, delivery and performance
of this Agreement.

 

(g)          Investment
Purpose. Each Rollover Stockholder,

 

(i)          is
acquiring the Parent Interests for investment for his, her or its own account and not with a view to, or for sale in connection
with, any distribution thereof;

 

(ii)         either
alone or together with his, her or its advisors, has sufficient knowledge and experience in financial and business matters so as
to be capable of evaluating the merits and risks of his, her or its investment in the Parent Interests and is capable, without
impairing such Rollover Stockholder’s financial condition, of bearing the economic risks of such investment, including the
risk of the complete loss thereof, for an indefinite period of time;

 

(iii)        either
alone or together with his, her or its advisors, has reviewed all documents provided to it in connection with the investment in
the Parent Interests;

 

(iv)        either
alone or together with his, her or its advisors, has been given the opportunity to examine all documents and to ask such questions
as he, she or it has deemed necessary of, and to receive answers from, Parent and its representatives concerning the terms and
conditions of the investment in the Parent Interests, the merits and risks of owning the Parent Interests and related matters and
to obtain all additional information which such Rollover Stockholder and his, her or its advisors deem necessary;

 

(v)         has
been advised to discuss with his, her or its own counsel the meaning and legal consequences of such Rollover Stockholder’s
representations and warranties in this Agreement and the transactions contemplated hereby;

 

(vi)        has
relied only on his, her or its own tax advisor and not Parent, the other Stockholders, the Company or any of their respective advisors,
with respect to United States federal, state, local, foreign and other tax consequences arising from such Rollover Stockholder’s
acquisition, ownership and disposition of the Parent Interests;

 

(vii)       understands
and acknowledges that the Parent Interests acquired hereunder are a speculative investment which involves a high degree of risk
of loss of the entire investment therein; and

 

(viii)      understands
and acknowledges that the issuance of the Parent Interests will not have been registered under the Securities Act or any other
applicable securities laws (including such Laws of jurisdictions other than the United States), and, therefore, after issuance
such Parent Interests cannot be sold except in compliance with the Securities Act, such other applicable securities or “blue
sky” laws and that, accordingly, it may not be possible for such Rollover Stockholder to sell the Parent Interests in case
of emergency or otherwise.

 

(h)          Information.
Significant Stockholder has provided Parent and Sponsor with the final drafts of all written due diligence reports, if any, that
have been prepared by Significant Stockholder’s Advisors and received by Significant Stockholder as of the date of the Original
Support Agreement in connection with the Company, the Merger and the other transactions contemplated by the Merger Agreement.

 

    	- 9 -

    	 

    

 

8.           Representations
and Warranties of Parent. Parent hereby represents and warrants to the Stockholders as follows:

 

(a)          Organization.
Parent is an exempted limited partnership duly organized, validly existing and in good standing under the Laws of Cayman Islands
and has the requisite power and authority to own or lease all of its properties and assets and to carry on its business as it is
now being conducted. Parent is duly licensed or qualified to do business in each jurisdiction in which the nature of the business
conducted by it or the character or location of the properties and assets owned or leased by it makes such licensing or qualification
necessary, except where the failure to be so licensed or qualified would not constitute, individually or in the aggregate, a Parent
Material Adverse Effect.

 

(b)          Power;
Binding Agreement. Parent has all necessary power and authority to execute and deliver this Agreement and to consummate
the transactions contemplated hereby. The execution, delivery and performance by Parent of this Agreement, and the consummation
by Parent of the transactions contemplated hereby, have been duly authorized and approved by Parent, and no other action on the
part of Parent or its general or limited partners is necessary to authorize the execution and delivery by Parent of this Agreement
and the consummation by Parent of the transactions contemplated hereby. This Agreement has been duly executed and delivered by
Parent and, assuming due and valid authorization, execution and delivery of this Agreement by the other parties hereto, constitutes
a valid and binding obligation of Parent, enforceable against Parent in accordance with its terms, except that such enforceability
(i) may be limited by bankruptcy, insolvency, moratorium or other similar Laws affecting or relating to the enforcement of creditors’
rights generally and (ii) is subject to general principles of equity.

 

(c)          No
Conflicts. None of the execution and delivery by Parent of this Agreement and the consummation by Parent of the transactions
contemplated hereby, and compliance by Parent with any of the terms and provisions of this Agreement, will (i) violate any provision
of its organizational documents or (ii) (x) violate any Law applicable to Parent or any of its properties or assets or (y) violate,
result in the loss of any material benefit under, constitute a default (or an event which, with notice or lapse of time, or both,
would constitute a default) under, result in the termination of or a right of termination or cancellation under, accelerate the
performance required by, or result in the creation of any Lien upon any of the properties or assets of Parent under any Contract
to which Parent is a party, or by which Parent or any of its properties or assets may be bound or affected, except, in the case
of clause (ii) above, for such violations, losses of benefits, defaults, events, terminations, rights of termination or cancellation,
accelerations or Lien creations as would not constitute, individually or in the aggregate, a Parent Material Adverse Effect.

 

(d)          Issuance
of Parent Interests. The Parent Interests will be duly authorized, validly issued, fully paid and nonassessable, and free and
clear of all Encumbrances, preemptive rights, rights of first refusal, subscription and similar rights (other than those arising
under any agreements entered into at the Contribution Closing by any Stockholders) when issued.

 

(e)          Information.
Parent and Sponsor have provided Significant Stockholder with (i) the final drafts of all written due diligence reports that have
been prepared by Parent’s or Sponsor’s Advisors and received by Parent or Sponsor as of the date of the Original Support
Agreement in connection with the Company, the Merger and the other transactions contemplated by the Merger Agreement and (ii) true
and accurate copies of the following corporate documents: (x) the registration certificate, registration statement and register
of partnership interests of Parent and (y) the certificate of incorporation, by-laws and list of directors of Merger Sub.

 

    	- 10 -

    	 

    

 

(f)          Additional
Representations and Warranties. Parent hereby makes the same representations and warranties with respect to itself and Merger
Sub as Parent makes to the Company under Sections 5.1, 5.2, 5.3, 5.4, 5.6, 5.9, 5.11 and 5.12 of the Merger Agreement.

 

9.           Additional
Covenants.

 

(a)          Reasonable
Best Efforts to Enter Into Shareholders Agreement. Promptly following the date of the Original Support Agreement, Parent, Sponsor
and the Rollover Stockholders shall in good faith and with mutual cooperation use their reasonable best efforts to negotiate and
enter into a shareholders agreement which shall reflect the terms set forth in the term sheet (the “Term Sheet”)
attached as Exhibit B hereto (the “Shareholders Agreement”), effective as of the Effective Time and providing
for certain rights, duties and obligations of each Person proposed to be a party thereto. In the event Parent, Sponsor and the
Rollover Stockholders have not entered into the Shareholders Agreement as of the Effective Time, each of them hereby agrees to
use its, his or her best efforts to implement the terms set forth in the Term Sheet and carry out the intention of the parties
contained in the Term Sheet to the closest extent as possible.

 

(b)          Reasonable
Efforts to Call Significant Stockholder Parent’s Meeting. Fosun Industrial Co., Limited a corporation organized under
the laws of Hong Kong (“Significant Stockholder”), shall (i) use its reasonable efforts to cause its sole stockholder,
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a corporation incorporated under the Laws of China (“Significant Stockholder
Parent”), to call, give notice of, convene and hold a special meeting (the “Significant Stockholder Parent’s
Meeting”) of the stockholders of Significant Stockholder Parent for the purposes of considering and voting on the approval
(the “Requisite Significant Stockholder Stockholder Approval”) for it to perform its obligations under the Merger
Agreement, this Agreement, the Significant Stockholder Equity Commitment Letter, the letter of commitment pursuant to which it
has committed, subject to the terms and conditions therein including the receipt of the Requisite Significant Stockholder Stockholder
Approval, to subscribe for limited partnership interests of Parent (the “Significant Stockholder Letter of Commitment”
and, together with a substantially similar letter of commitment provided by Sponsor, the “Letters of Commitment”),
the Subscription Agreement (as defined below), the Commitment for Acquisition of 30% Shareholding in Healthy Medical Limited between
Significant Stockholder and Parent dated February 17, 2014 and the Service Fees Letter Agreement between Parent and Significant
Stockholder dated February 17, 2014 (collectively, the “Significant Stockholder Transactions”) as soon as reasonably
practicable; provided that Significant Stockholder Parent may delay or postpone convening the Significant Stockholder Parent’s
Meeting, or adjourn the Significant Stockholder Parent’s Meeting beyond the time that the Significant Stockholder Parent’s
Meeting would otherwise be held, (A) with the prior written consent of Parent and the Company (such consent not to be unreasonably
withheld, delayed or conditioned), (B) for the absence of a quorum, (C) to allow reasonable additional time for any supplemental
or amended disclosure which Significant Stockholder has determined in good faith (after consultation with Significant Stockholder
Parent’s outside counsel) is necessary under applicable Law and for such supplemental or amended disclosure to be disseminated
and reviewed by Significant Stockholder Parent’s stockholders prior to the Significant Stockholder Parent’s Meeting,
or (D) to allow additional solicitation of votes in order to obtain the Requisite Significant Stockholder Stockholder Approval,
(ii) not take any action to frustrate the calling, giving notice of, convening and holding of the Significant Stockholder Parent’s
Meeting by Significant Stockholder Parent, and (iii) cause the parent company of Significant Stockholder Parent, Shanghai Fosun
High Technology (Group) Co., Ltd., to execute, within ten (10) Business Days of the Original Support Agreement, the Voting Agreement.

 

(c)          Cooperation.
Each of Parent, Sponsor and the Rollover Stockholders shall use its commercially reasonable efforts to take, or cause to be taken,
all actions, to file, or cause to be filed, all documents and to do, or cause to be done, and to assist and cooperate with the
other parties hereto in 

 

    	- 11 -

    	 

    

 

doing, all things necessary,
proper or advisable to consummate the Transactions, including (i) by submitting to MOFCOM the requisite filing for the Transactions
pursuant to the AML required under Section 6.5 of the Merger Agreement, and preparing and filing all necessary documentation to
effect, and using commercially reasonable efforts to obtain, all necessary permits, consents, approvals and authorizations of
all Governmental Entities necessary for consummating the Transactions, (ii) by supplying or providing information that is complete
and accurate in all material respects to any Governmental Entity requesting such information in connection with filings, consents,
approvals, authorizations or other actions that are required in order to satisfy any closing conditions under Section 7.1(b) of
the Merger Agreement, including with respect to the AML approval, (iii) by not engaging in any action or entering into any transaction
or permitting any action to be taken and using its commercially reasonable efforts to cause its non-controlled Affiliates (with
respect to Significant Stockholder, only the Significant Stockholder Parent and its Subsidiaries) not to engage in any action
or enter into any transaction or permit any action to be taken in violation of Section 6.8(c) of the Merger Agreement and (iv)
by providing such information concerning itself, herself or himself required to be included in the Proxy Statement and the Schedule
13E-3 (including any updates or supplements thereto).

 

(d)          Enforcement
Actions. With respect to each Letter of Commitment, any action to be taken by Parent (or any subsidiary thereof) in
connection therewith, including without limitation (i) the approval of the terms of the subscription agreement (as it may be amended,
supplemented or otherwise modified from time to time, the “Subscription Agreement”), the form of which is attached
to such Letter of Commitment, and authorization of Parent to enter into such definitive agreement and (ii) the taking of any action
to enforce the rights of Parent under such Letter of Commitment and under the terms of such Subscription Agreement, shall be taken
by, or at the direction of, the board of directors of Healthy Harmony GP, Inc., the general partner of Parent, with all representatives
of the party that issued such Letter of Commitment to Parent on the board of directors of Healthy Harmony GP, Inc. abstaining from
any vote relating to such action. In furtherance of the agreements contemplated herein and in the other ancillary agreements, the
parties hereto agree to use reasonable best efforts to take such actions as are necessary in order to give effect to the provisions
of this Section 9(d).

 

(e)          Access
to Information. Parent and Sponsor, on the one hand, and Significant Stockholder, on the other, shall (i) share with each other
(A) all material information provided by the Company to it between the date of the Original Support Agreement and the Closing,
(B) all final written drafts of the due diligence reports and/or opinions prepared by its Advisors between the date of the Original
Support Agreement and the Closing and received by it in connection with the Company, the Merger and the other transactions contemplated
by the Merger Agreement, and (C) (x) with respect to Parent and Sponsor, all information regarding Parent and Merger Sub and information
regarding the Stockholders and Additional Rollover Stockholders relating to the Merger and the other transactions contemplated
by the Merger Agreement that is in their possession, in each case as reasonably requested by Significant Stockholder, and (y) with
respect to Significant Stockholder, all information regarding it relating to the Merger and the other transactions contemplated
by the Merger Agreement, as reasonably requested by Parent or Sponsor, in each case except to the extent provided in the electronic
data room established by the Company for the purposes of the Merger and the other transactions contemplated by the Merger Agreement,
and (ii) provide prompt responses to reasonable requests by the other party for information relating to the Merger and the other
transactions contemplated by the Merger Agreement.

 

(f)          Consent
of Significant Stockholder. Without the prior written consent of Significant Stockholder, Parent shall not take any action
in relation to the Transactions other than (i) day-to-day communication with respect to the Transactions if such communication
does not involve any decision-making; provided that a representative designated by Significant Stockholder from time to
time shall be provided reasonable prior notice of such communication and shall have the right to participate in such day-to-day
communication, (ii) enforcement of its rights against Significant Stockholder in the event

 

    	- 12 -

    	 

    

 

of a breach by Significant Stockholder
of the Significant Stockholder Equity Commitment Letter and this Agreement, provided that Parent shall, at the direction
of Significant Stockholder, also enforce its rights against Sponsor in the event of a breach by Sponsor
of the Equity Commitment Letter and this Agreement to the same extent, and (iii) any action required by Law; provided that
Parent shall notify Significant Stockholder in writing within two (2) days after taking such action. Significant Stockholder shall
provide its response within two (2) days after it receives any request for such consent from Parent and, in the case of a rejection,
together with an explanation therefor. Without limiting the generality of the above, without the prior written consent of Significant
Stockholder, Parent shall not (i) agree to amend any term, waive any condition under, or terminate the Merger Agreement or the
agreements or arrangements referred to in Section 5.8 of the Parent Disclosure Schedule or (ii) enter into any Additional Rollover
Agreement.

 

(g)          Reconciliation
Report. Significant Stockholder shall use its reasonable best efforts to deliver, by the five (5)-month anniversary of February
17, 2014, to Parent and the Company a copy of the report to be prepared by Ernst & Young or another accounting firm to be retained
by Significant Stockholder (subject to the approval of Parent, such approval not to be unreasonably withheld or delayed) on the
reconciliation between the consolidated financial statements of the Company prepared in accordance with GAAP and generally accepted
accounting principles in China (or such other report as may be required under the rules of any stock exchange on which any shares
of Significant Stockholder Parent may be listed) for inclusion in the notice (or any accompanying materials) for the Significant
Stockholder Parent’s Meeting; provided that the Company shall have promptly provided all information reasonably requested
by Significant Stockholder in connection with the preparation of such report.

 

10.          Expenses
and Fee Sharing.

 

(a)          If
the Transactions are consummated, then, at or immediately following the Closing, the Surviving Corporation shall reimburse the
parties for, or pay on behalf of the parties, as the case may be, all of the reasonable documented fees and out-of-pocket costs
and expenses incurred by each party in connection with the Transactions, including the reasonable fees, expenses and disbursements
of legal, accounting, banking and other advisors and/or consultants of (x) Parent and Merger Sub and (y) of each other party, which
appointments have been approved by Sponsor and Significant Stockholder in advance (collectively, “Advisors”).

 

(b)          Subject
to Section 10(f), (i) if the Transactions are terminated or this Agreement is terminated prior to the Closing pursuant to
Section 14 and (ii) Section 10(c) does not apply, Sponsor agrees to bear 63% and Significant Stockholder agrees to
bear 37% of the reasonable documented fees and out-of-pocket costs and expenses in connection with the Transactions incurred prior
to the termination of this Agreement that are payable by (x) Parent, Merger Sub, Sponsor and Significant Stockholder to their respective
Advisors and (y) the Management Stockholders to the Advisors jointly retained by them, which appointments have been approved by
the Sponsor and Significant Stockholder in advance, in the case of clause (y), in a total amount not in excess of US$750,000.

 

(c)          If
the Transactions are not consummated or this Agreement is terminated prior to the Closing due to the  breach of any provision
set forth under this Agreement or the Equity Commitment Letter, if applicable, by one or more parties other than Elyse Silverberg
and Lawrence Pemble (each a “Breaching Party”), then such Breaching Parties shall reimburse any non-breaching
party other than Elyse Silverberg and Lawrence Pemble for all fees and out-of-pocket costs and expenses incurred in connection
with the Transactions, including (x) any fees and expenses of the Advisors retained by such non-breaching party and (y) any Parent
Termination Fee and/or Parent Expense Reimbursement or other damages or losses payable to the Company.  If there is more than
one Breaching Party, each such Breaching Party shall be severally liable for its pro rata share of the fees and expenses based
on such Breaching Party’s contemplated ownership of Parent upon the consummation of the Transactions vis-a-vis 

 

    	- 13 -

    	 

    

 

the contemplated
ownership of Parent of the other Breaching Party upon the consummation of the Transactions. The foregoing shall be without prejudice
to any rights and remedies otherwise available to a non-breaching party. For the avoidance of doubt, subject to Significant Stockholder
having complied with its obligations under this Agreement, the failure to obtain the Requisite Significant Stockholder Stockholder
Approval shall not be deemed as breach of any provision under this Agreement.

 

(d)          For
the avoidance of doubt, the parties acknowledge that (i) Cleary Gottlieb Steen & Hamilton LLP has been engaged as international
legal counsel to provide international legal services to Sponsor in connection with the Transactions and this Agreement in addition
to it acting as the international legal counsel to Parent and Merger Sub in connection with the Transactions; (ii) Baker &
McKenzie and Troutman Sanders LLP have been engaged as international legal counsels to provide international legal services to
Significant Stockholder and (iii) Skadden Arps Slate Meagher & Flom LLP has been engaged as international legal counsel to
provide international legal services to Management Stockholders in connection with the Transactions and this Agreement. The parties
further acknowledge that (w) PricewaterhouseCoopers LLP has been engaged as accounting advisor, (x) Fangda Partners has been engaged
as PRC legal counsel, (y) McKinsey has been engaged as industry consultant and (z) Goldman Sachs has been engaged as financial
advisor, in each case to Parent and Merger Sub in connection with the Transactions.

 

(e)          Sponsor
and Significant Stockholder shall be entitled to receive, on an equal basis, any termination or other fees or amounts payable to
Parent or Merger Sub by the Company pursuant to the Merger Agreement, net of the expenses required to be borne by them pursuant
to this Section 10.

 

(f)          The
obligation of Sponsor, Significant Stockholder and Management Stockholders under this Agreement is several (and not joint or joint
and several).

 

11.          No
Legal Actions. Each Stockholder agrees that such Stockholder shall not, in Stockholder’s capacity as a stockholder of
the Company, bring, commence, institute, maintain, prosecute or join any Proceeding, in law or in equity, in any court or before
any Governmental Entity, which (i) challenges the validity of or seeks to enjoin the operation of any provision of this Agreement
or the Merger Agreement or (ii) alleges that the execution and delivery of this Agreement by the Stockholders, and proxies to be
delivered in connection with the execution of the Merger Agreement, or the approval of the Merger Agreement by the Company Board,
breaches any fiduciary duty of the Company Board or any member thereof.

 

12.          Non-Solicitation.
Each Stockholder shall not, and shall instruct his, her or its Representatives not to, directly or indirectly (a) initiate, solicit
or knowingly encourage any inquiries, discussions or proposals regarding any Alternative Proposal (including by providing non-public
information to any Person for the purpose of making, evaluating, or determining whether to make or pursue, any inquiries or proposals
with respect to any Alternative Proposal), (b) continue, propose, enter into or participate in any way in negotiations or discussions
with respect to any Alternative Proposal, or (c) enter into any letter of intent, agreement in principle, acquisition agreement
or other agreement or understanding providing for any Alternative Proposal; provided, however, that notwithstanding
anything to the contrary contained in this Agreement, each Stockholder shall be permitted to (i) inform any Person of the existence
of the provisions contained in this Agreement, (ii) contact any Person or group of Persons who has made an Alternative Proposal
to clarify and understand the terms and conditions thereof, (iii) engage or participate in discussions or negotiations with,
provide information to or fully cooperate with, the Person or group of Persons who has made a bona fide Alternative Proposal,
the Company, and the Representatives of the Person or group of Persons who has made such Alternative Proposal or the Company regarding
such Alternative Proposal or otherwise facilitate or fully participate in such Alternative Proposal, (iv) take any other
action that would be permissible for the Company to take under

 

    	- 14 -

    	 

    

 

Section 6.2 of the Merger Agreement or (v) to take any action
with respect to any Alternative Proposal, including entering into any letter of intent, agreement in principle, acquisition agreement
or other agreement or understanding with respect to such Stockholder’s Shares, future employment or otherwise; provided
that each Stockholder may take the actions set forth in clauses (iii), (iv) and (v) above if, and only during such time as, the
Company is permitted, under Section 6.2 of the Merger Agreement, to have discussions or negotiations with respect to such Alternative
Proposal.

 

13.          Further
Assurances. Subject to Section 12, each Stockholder hereby covenants that, from time to time, such Stockholder
will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, such further acts, conveyances,
transfers, assignments, powers of attorney and assurances necessary to convey, transfer to and vest in Parent, and to put Parent
in possession of, all of the applicable Shares in accordance with the terms of this Agreement.

 

14.          Termination.
This Agreement and each Proxy, and all rights and obligations of the parties hereunder and thereunder, shall terminate, shall be
null and void and shall have no further force or effect from and after the Expiration Date, and upon such termination no party
hereto shall have any further obligations or liabilities under this Agreement. Notwithstanding the foregoing, nothing set forth
in this Section 14 shall relieve any party hereto from liability, or otherwise limit the liability of any party hereto,
for any breach of this Agreement prior to such termination. This Section 14, Section 1, Section 10 and
Section 17 (as applicable) shall survive any termination of this Agreement. If for any reason the Merger contemplated
by the Merger Agreement fails to occur but the Contribution Closing has already taken place, then Parent shall promptly return
the Share Documents to the Stockholders at their respective addresses set forth on Schedule A and take all such actions
as are necessary to restore each such Stockholder to the position he, she, or it was in with respect to ownership of the Shares
prior to the Contribution Closing.

 

15.          Survival
of Representations and Warranties. All representations and warranties of the Stockholders or by or on behalf of Parent in connection
with the transactions contemplated by this Agreement contained herein shall survive the execution and delivery of this Agreement,
any investigation at any time made by or on behalf of Parent or the Stockholders, and the issuance of the Parent Interests.

 

16.          Publicity.
So long as this Agreement is in effect, subject to the proviso in Section 12 none of the Stockholders or any of their respective
Affiliates shall issue or cause the publication of any press release or other announcement with respect to the Merger, this Agreement
or any of the other transactions contemplated hereby or thereby without the prior written approval of Parent, except as may be
required by Law or by the rules of any applicable securities exchange as determined in the good faith judgment of the Stockholder
wanting to make such release or announcement, in which event such Stockholder shall use its reasonable best efforts to provide
a meaningful opportunity to Parent to review and comment upon such press release or announcement prior to making it.

 

17.          Miscellaneous.

 

(a)          Validity.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void,
unenforceable or against its regulatory policy, the remainder of the terms, provisions, covenants and restrictions of this Agreement
shall nevertheless remain in full force and effect and shall in no way be affected, impaired or invalidated. Upon such determination
that any term, provision, covenant or restriction is invalid, illegal, void, unenforceable or against regulatory policy, the parties
hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties hereto as closely
as possible in an acceptable manner in order that the transactions contemplated hereby are consummated as originally contemplated
to the greatest extent possible.

 

    	- 15 -

    	 

    

 

(b)          Binding
Effect and Assignment. Neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned
by any of the parties hereto, in whole or in part (whether by operation of law or otherwise), without the prior written consent
of the other parties hereto. Subject to the preceding sentence, this Agreement shall be binding upon, inure to the benefit of and
be enforceable by the parties and their respective successors and permitted assigns. Any purported assignment in violation of the
provisions of this Agreement shall be null and void ab initio.

 

(c)          Amendments;
Waiver. This Agreement may be amended by the parties hereto, and the terms and conditions hereof may be waived, only
by an instrument in writing signed on behalf of each of the parties hereto, or, in the case of a waiver, by an instrument signed
on behalf of the party waiving compliance; provided, however, that the Company’s consent shall be required
for any amendment to or waiver of Sections 2, 4, 6, 9(b), 9(c) and 12 of this
Agreement.

 

(d)          Specific
Performance; Injunctive Relief. The parties hereto acknowledge that each party shall be irreparably harmed and that
there shall be no adequate remedy at law for a violation of any of the covenants or agreements set forth herein by the other party.
Therefore, it is agreed that, in the event that any covenant or agreement in this Agreement is not performed in accordance with
its terms, each party hereto shall have the right to enforce such covenants and agreements pursuant to a temporary restraining
order, specific performance, injunctive relief or by any other means available in equity, without the requirement of posting a
bond or other security. Each party hereto further agrees that a party may only seek monetary remedies if the foregoing remedies
are unavailable or are inadequate to remedy such violation or non-performance of any such covenant or agreement. The parties agree
that under no circumstances shall any party hereto be permitted or entitled to receive a duplicative grant of specific performance
and payment of monetary remedies. Subject to the provisions of this Section 17(d), all rights, powers and remedies provided
under this Agreement or otherwise available in respect hereof at law or in equity shall be cumulative and not alternative, and
the exercise or beginning of the exercise of any thereof by any party shall not preclude the simultaneous or later exercise of
any other such right, power or remedy by such party.

 

(e)          Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered
via facsimile or electronic mail and receipt is confirmed, at the facsimile telephone number or email address specified in this
Section 17(e), prior to 5:00 p.m., New York City time, on a Business Day, (ii) the first Business Day after the date
of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this
Section 17(e) (x) at or after 5:00 p.m., local time of the receiving party, on a Business Day or (y) on a day that is not
a Business Day, (iii) when received, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt
by the party to whom such notice is required or permitted to be given. The address for such notices and communications (unless
changed by the applicable party by like notice) shall be as follows:

 

If to Parent:

 

c/o TPG Capital, L.P.

345 California Street, Suite 3300, San Francisco, CA 94104

Attention: Ronald Cami, Esq.

Telephone No.: (415) 743-1532

Facsimile No.: (415) 743-1501

Email address: rcami@tpg.com

 

    	- 16 -

    	 

    

 

with copies (which shall not constitute notice or
constructive notice) to:

 

Cleary Gottlieb Steen & Hamilton LLP

Twin Towers - West (23Fl), Jianguomenwai Da Jie

Chaoyang District

Beijing 100022, China

Attention: Ling Huang

Telephone No.: (86) 10 5920-1000

Facsimile No: (852) 2160-1087

Email address: lhuang@cgsh.com

 

and

 

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, NY 10006

Attention: Victor Lewkow

Telephone No.: (212) 225-2000

Facsimile No: (212) 225-3999

Email address: vlewkow@cgsh.com

 

If to Sponsor:

 

c/o TPG Capital, L.P.

345 California Street, Suite 3300, San Francisco, CA 94104

Attention: Ronald Cami, Esq.

Telephone No.: (415) 743-1532

Facsimile No.: (415) 743-1501

Email address: rcami@tpg.com

 

with copies (which shall not constitute notice or
constructive notice) to:

 

Cleary Gottlieb Steen & Hamilton LLP

Twin Towers - West (23Fl), Jianguomenwai Da Jie

Chaoyang District

Beijing 100022, China

Attention: Ling Huang

Telephone No.: (86) 10 5920-1000

Facsimile No: (852) 2160-1087

Email address: lhuang@cgsh.com

 

and

 

Cleary Gottlieb Steen & Hamilton LLP

One Liberty Plaza

New York, NY 10006

Attention: Victor Lewkow

Telephone No.: (212) 225-2000

Facsimile No: (212) 225-3999

Email address: vlewkow@cgsh.com

 

    	- 17 -

    	 

    

 

If to any Stockholder, in accordance with the contact
information set forth next to such Stockholder’s name on Schedule A.

 

(f)          Headings.
The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation
of this Agreement.

 

(g)          No
Waiver. The failure of any party hereto to exercise any right, power or remedy provided under this Agreement or otherwise
shall not constitute a waiver by such party of such party’s right to exercise any such or other right, power or remedy or
to demand such compliance nor shall any single or partial exercise of any such rights preclude any other or further exercise thereof.

 

(h)          No
Third Party Beneficiaries. This Agreement is not intended to, and shall not, confer any rights or remedies upon any
Person other than the parties hereto; provided, however, that the Company is an express third party beneficiary of
Sections 2, 4, 6, 9(b), 9(c) and 12 of this Agreement.

 

(i)          Governing
Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware that apply
to agreements made and performed entirely within the State of Delaware, without regard to the conflicts of laws provisions thereof
or of any other jurisdiction.

 

(j)          Consent
to Jurisdiction. Parent, Sponsor and each Stockholder hereby agrees that any Proceeding arising out of or relating to
this Agreement or any of the transactions contemplated hereby shall be brought and determined in the Court of Chancery of the State
of Delaware or, if exclusive jurisdiction over the matter is vested in the federal courts, any court of the United States located
in the State of Delaware (and each such party shall not bring any Proceeding arising out of or relating to this Agreement or any
of the transactions contemplated hereby in any court other than the aforesaid courts), and Parent, Sponsor and each Stockholder
hereby irrevocably submits with regard to any such Proceeding for himself, herself or itself and in respect to his, her or its
property, generally and unconditionally, to the exclusive jurisdiction of the aforesaid courts. Parent, Sponsor and each Stockholder
hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any such Proceeding,
(i) any claim that he, she or it is not personally subject to the jurisdiction of the above-named courts for any reason other than
the failure to lawfully serve process, (ii) that he, she or it or his, her or its property is exempt or immune from jurisdiction
of such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment,
attachment in aid of execution of judgment, execution of judgment or otherwise), and (iii) that (x) such Proceeding in any such
court is brought in an inconvenient forum, (y) the venue of such Proceeding is improper and (z) this Agreement, the transactions
contemplated hereby or the subject matter hereof, may not be enforced in or by such courts.

 

(k)          Waiver
of Jury Trial. PARENT, SPONSOR AND EACH STOCKHOLDER ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS
AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, PARENT, SPONSOR AND EACH STOCKHOLDER IRREVOCABLY
AND UNCONDITIONALLY WAIVES ANY RIGHT HE, SHE OR IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY PROCEEDING ARISING OUT OF OR
RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY. PARENT, SPONSOR AND EACH STOCKHOLDER CERTIFIES AND
ACKNOWLEDGES THAT (I) NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD
NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF ANY SUCH PROCEEDING, (II) SUCH PARTY HAS CONSIDERED THE IMPLICATIONS
OF THIS WAIVER, (III) SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (IV) SUCH

 

    	- 18 -

    	 

    

 

PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER
THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 17(k).

 

(l)          Rules
of Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. Consequently,
in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly
by the parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provision of this Agreement.

 

(m)          Entire
Agreement. This Agreement (together with the Merger Agreement and any other documents and instruments referred to herein
or therein) constitutes the entire agreement, and supersedes all other prior agreements and understandings, both written and oral,
among the parties and their Affiliates, or any of them, with respect to the subject matter hereof.

 

(n)          Interpretation.

 

(i)          Whenever
the words “include”, “includes” or “including” are used in this Agreement they shall be deemed
to be followed by the words “without limitation”.

 

(ii)         The
article and section headings contained in this Agreement are for reference purposes only and shall not in any way affect or be
deemed to affect the meaning or interpretation of this Agreement.

 

(iii)        Words
describing the singular number shall be deemed to include the plural and vice versa, and words denoting any gender shall be deemed
to include all genders.

 

(o)          Counterparts;
Facsimile Transmission of Signatures. This Agreement may be executed in two (2) or more counterparts, all of which shall
be considered one and the same agreement, and shall become effective when each party has received counterparts signed by each of
the other parties, it being understood and agreed that delivery of a signed counterpart of this Agreement by facsimile transmission
or by email shall constitute valid and sufficient delivery thereof.

 

[Remainder of Page Intentionally Left Blank]

 

    	- 19 -

    	 

    

 

IN WITNESS WHEREOF, the
undersigned have executed and caused to be effective this Agreement as of the date first above written.

 

HEALTHY HARMONY HOLDINGS, L.P.

By: Healthy Harmony GP, Inc., its general partner

 

	By:	/s/ Ronald Cami	 
	Name: Ronald Cami	 
	Title: Vice President	 
	 	 
	TPG ASIA VI, L.P.	 
	By: TPG Asia GenPar VI, L.P., its general partner
	By: TPG Asia GenPar VI Advisors, Inc., its general partner
	 	 
	By:	/s/ Ronald Cami	 
	Name: Ronald Cami	 
	Title: Vice President	 

 

[Signature Page to First Amended and Restated
Support Agreement]

 

    	 

    	 

    

 

	STOCKHOLDERS	 
	 	 
	Roberta Lipson	 
	 	 
	By:	/s/ Roberta Lipson	 
	 	 
	Elyse Silverberg	 
	 	 
	By:	/s/ Elyse Silverberg	 
	 	 
	Lawrence Pemble	 
	 	 
	By:	/s/ Lawrence Pemble	 
	 	 
	FOSUN INDUSTRIAL CO., LIMITED	 
	 	 
	By:	/s/ Qiyu Chen	 
	 	 
	Name:  Qiyu Chen	 
	 	 
	Title:  Chairman of the Board of Directors	 

 

[Signature Page to First Amended and Restated
Support Agreement]

 

    	 

    	 

    

 

STOCKHOLDERS

 

Roberta Lipson, as trustee of the Benjamin Lipson Plafker Trust

 

	By:	/s/ Roberta Lipson	 
	 	 
	Roberta Lipson, as trustee of the Daniel Lipson Plafker Trust
	 	 
	By:	/s/ Roberta Lipson	 
	 	 
	Roberta Lipson, as trustee of the Jonathan Lipson Plafker Trust
	 	 
	By:	/s/ Roberta Lipson	 
	 	 
	Roberta Lipson, as trustee of the Ariel Benjamin Lee Trust
	 	 
	By:	/s/ Roberta Lipson	 

 

[Signature Page to First Amended and Restated
Support Agreement]

 

    	 

    	 

    

 

EXHIBIT A

 

IRREVOCABLE PROXY

 

The undersigned Stockholder
(the “Stockholder”) of Chindex International, Inc., a Delaware corporation (the “Company”),
hereby, as of __________________, 2014, irrevocably (to the fullest extent permitted by law) appoints Healthy Harmony Holdings,
L.P., a Cayman Island limited partnership (“Parent”), acting through its authorized signatories (provided that
any such signatory is an Affiliate of Parent and is acting on its behalf), as the sole and exclusive attorney and proxy of the
undersigned, with full power of substitution and resubstitution, to vote and exercise all voting and related rights (to the full
extent that the undersigned is entitled to do so) with respect to all of the shares of capital stock of the Company that now are
or hereafter may be beneficially owned by the undersigned, and any and all other shares or equity securities of the Company issued
or issuable in respect thereof on or after the date hereof (collectively, the “Shares”) in accordance with the
terms of this Irrevocable Proxy until the Expiration Date (as defined below); provided, however, that such proxy
and voting and related rights are expressly limited to the matters discussed in clauses (i) and (ii) in the fourth paragraph of
this Irrevocable Proxy. Upon the undersigned’s execution of this Irrevocable Proxy, any and all prior proxies given by the
undersigned with respect to any Shares are hereby revoked and the undersigned agrees not to grant any subsequent proxies with respect
to the Shares until the Expiration Date, provided, that the undersigned may grant subsequent proxies with respect to any
matter other than those discussed in clauses (i) and (ii) in the fourth paragraph of this Irrevocable Proxy.

 

This Irrevocable Proxy
is irrevocable to the fullest extent permitted by Section 212 of the DGCL, is coupled with an interest sufficient in law and is
granted pursuant to that certain Support Agreement dated as of __________________, 2014 by and between Parent and the undersigned
Stockholder (as may be amended, supplemented or otherwise modified from time to time, the “Support Agreement”),
and is granted as a condition and inducement to the willingness of Parent, Healthy Harmony Acquisition, Inc., a Delaware corporation
and a wholly owned subsidiary of Parent (“Merger Sub”) to enter into that certain Agreement and Plan of Merger
dated as of February 17, 2014, which was subsequently amended and restated on April 18, 2014 (as it may be further amended, supplemented
or otherwise modified from time to time, the “Merger Agreement”), among Parent, Merger Sub and the Company.
The Merger Agreement provides for, among other things, the merger of Merger Sub with and into the Company (the “Merger”)
with the Company continuing as the surviving corporation of the Merger. 

 

As used herein, the
term “Expiration Date” shall mean the earliest to occur of (i) the Effective Time, (ii) the date and time the
Merger Agreement is terminated in accordance with its terms and provisions, and (iii) the effectiveness of a mutual written agreement
of the parties hereto to terminate this Proxy. All capitalized terms that are used but not defined herein shall have the respective
meanings ascribed to them in the Support Agreement.

 

The attorney and proxy
named above is hereby authorized and empowered by the undersigned, at any time prior to the Expiration Date, to act as the undersigned’s
attorney and proxy to vote the Shares, and to exercise all voting, consent and similar rights of the undersigned with respect to
the Shares (including, without limitation, the power to execute and deliver written consents) at every annual, special, adjourned
or postponed meeting of stockholders of the Company and in every written consent in lieu of such meeting:

 

(i)          in
favor of (A) the approval and adoption of the Merger Agreement (as it may be amended, supplemented or otherwise modified from time
to time), the approval of the Merger and the other transactions contemplated by the Merger Agreement and any other matter that
must be approved

 

    	 

    	 

    

 

 by the stockholders of the Company in order for the transactions contemplated by the Merger Agreement to be consummated
and (B) any adjournment, recess, delay or postponement recommended by the Company (and not publicly opposed by Parent) with respect
to any stockholder meeting with respect to the Merger Agreement and the Merger; and

 

(ii)         against
any of the following actions and matters (other than those in furtherance of the Merger and the Merger Agreement): (A) any
Alternative Proposal with respect to the Company, (B) any adjournment, recess, delay or postponement of any stockholder meeting
with respect to the Merger Agreement and the Merger publicly opposed by Parent, or (C) any other action or matter that (1) would
reasonably be expected to materially impede, interfere with, delay, postpone, discourage or adversely affect the timely consummation
of the Merger or any other transactions contemplated by the Merger Agreement or (2) would reasonably be expected to result in a
material breach of any covenant, representation or warranty, or any other obligation or agreement of the Company under the Merger
Agreement.

 

The attorney and proxy
named above may not exercise this Irrevocable Proxy on any other matter. The undersigned Stockholder may vote the Shares in his,
her or its sole discretion on all other matters. For the avoidance of doubt, clauses (i) and (ii) in the fourth paragraph of this
Irrevocable Proxy shall not apply to votes, if any, on the election or removal of directors as recommended by the Company Board
(provided [such recommendation is not in violation of the terms of the Merger Agreement]1/[Significant
Stockholder is complying with its obligations under Sections 2.1 and 2.2 of the Stockholder Agreement dated June 14, 2010 among
the Company, Significant Stockholder and Significant Stockholder Parent solely with respect to any matter upon which a vote, consent
or other approval is sought from the stockholders of the Company for the election or removal of directors of the Company (or relating
to procedures applicable to the election of directors)]2).

 

Any obligation of the
undersigned hereunder shall be binding upon the heirs, beneficiaries, executors, successors and permitted assigns of the undersigned.

 

This Irrevocable Proxy
shall terminate, and be of no further force and effect, automatically upon the Expiration Date.

 

[Remainder of page left intentionally blank]

 

 

1
To be inserted for Stockholder proxy other than the Significant Stockholder.

 

2
To be inserted for Significant Stockholder proxy.

  

    	 

    	 

    

 

IN WITNESS WHEREOF, the undersigned has
executed this Irrevocable Proxy as of the date first above written.

 

	STOCKHOLDER
	 	 
	By:	 	 

 

[Signature Page to Irrevocable Proxy]

 

    	 

    	 

    

 

EXHIBIT B

    

Project
Healthy

Shareholder Rights Term Sheet

 

This is a non-binding outline of the principal
terms relating to the corporate governance, transfer restrictions and exit options of Parent after the closing of the acquisition
of Healthy by Ms. Roberta Lipson, Ms. Elyse Silverberg and Mr. Lawrence Pemble (such individuals, the “Management Shareholders”),
TPG Asia VI, L.P. (“Sponsor”) and Fosun Industrial Co., Limited (“Significant
Shareholder”, and together with Sponsor and Management Shareholders, the “LP Holders”) and does not
constitute an offer or proposal capable of acceptance. It is for discussion purposes only.

 

	Post-Closing

 Capital

 Structure 	·     Sponsor
will own 47.6%, Management Shareholders will own 4.3%1
and Significant Shareholder will own 48.1% of the limited partnership interests (“LP Interests”) of Parent
post-closing, and Sponsor will own 48.1%, Management Shareholders will own 3.3% and Significant Shareholder will own 48.6% of
the LP Interests of Parent after the completion of the “Primary Financing Commitment” described below.2
	 	 
	Board of

 Directors	
        ·     The
        board of directors of Parent (the “Board”) will be comprised of 9 directors, including 3 appointed by Sponsor,
        3 appointed by Significant Shareholder, and 3 appointed by Management Shareholders (which three shall initially be Ms. Lipson,
        Ms. Silverberg and Mr. Pemble); provided that (i) each of Sponsor, Significant Shareholder and Roberta Lipson, on behalf
        of the Management Shareholders, shall have the right to (A) remove any director appointed by it or them, and (B) appoint the replacement
        for any retiring or removed director it or they initially appointed, subject to the approval of the Board, and (ii) any of the
        Sponsor, Significant Shareholder and Management Shareholders shall lose its or their rights to appoint (A) 1 director when it or
        they (as a group) no longer own at least 67% of the post-closing LP Interests owned by it or them, (B) 2 directors when it or they
        (as a group) no longer own at least 33% of the post-closing LP Interests owned by it or them and (C) any directors when it or they
        (as a group) no longer own any LP Interests.

         

        o     Each
        director shall be entitled to one vote on all matters that come before the Board and all decisions of the Board will require the
        approval of a majority of the directors, except as otherwise provided below under “Reserved Matters”.

         

        o     The
        quorum for any meeting of the Board shall be a simple majority of the directors, with at least 1 director appointed by each of
        Sponsor,

 

 

1
Share count information based on the Equity Incentive Plan and Shareholder Register as of February 7, 2014, respectively.
Existing options are calculated based on treasury method. Significant Stockholder will own 0.5% more LP Interests than Sponsor
upon closing.

2
The parties shall have the same ownership at the GP level as well as the LP level. The Board arrangements will be adopted
at the GP level. Assumes Primary Financing Commitments of US$130mm in total.

 

    	1

    	 

    

 

	 	
        Significant Shareholder and Management Shareholders
        present; provided that with respect to the enforcement of any right of the Company against any shareholder that would require the
        Board’s approval, the quorum requirement for the presence of such shareholder’s Board representative(s) shall be waived.

         

        ·     1
        director appointed by Sponsor and 1 director appointed by Significant Shareholder will be co-chair of the Board. If Ms. Lipson
        is removed as CEO for any reason other than a Violation of Law Removal, she will be appointed as sole chair of the Board as long
        as she remains a director of the Board.

         

        The rights of board designation will be replicated
        for Healthy and each wholly-owned direct subsidiary of Healthy, including Chindex Healthcare Holdings, Chindex Healthcare Holdings
        (Maritius), Chindex Medical Holdings (BVI) Ltd. and Chindex China Healthcare Finance LLC. Each of Sponsor and Significant Shareholder
        shall have the right to appoint an observer to the board of each of the indirect subsidiaries of Parent and receive a copy of all
        relevant board materials, subject to the approval of other shareholders in such indirect subsidiaries (if required); provided,
        however, that CEO shall use reasonable best efforts to secure such approval. Each director of the indirect subsidiaries
        of Parent appointed by a Group Company (as defined below) shall take all actions in accordance with the Board’s decisions
        and shall not take any action that is inconsistent with a resolution of the Board.

         

	Board

Committees	
        ·      The
        Board will form an Executive Committee with 3 members, consisting of 1 director appointed by Management Shareholders (which initially
        shall be Ms. Lipson), 1 director appointed by Sponsor and 1 director appointed by Significant Shareholder.

         

        o     The
        Executive Committee will meet at least once a month to discuss the management of Parent and its direct and indirect subsidiaries
        (collectively, the “Group” and each a “Group Company”) and will be responsible for implementing
        decisions and matters approved by the Board, including without limitation the following matters:

         

        §     Monthly
        review of operational and financial performance / key performance indicators

         

        §    Capital
        expenditures

         

        §    Financing

         

        §    IPO

         

        §    Mergers,
        acquisitions and other fundamental transactions.

         

        ·     Any
        transaction between any Group Company and CML that involves payment by or to any Group Company in an amount equal to or in excess
        of

 

    	2

    	 

    

 

	 	
        10% of the aggregate payment made in the previous
        fiscal year by or to the Group in each of the loan, equipment and consumables categories will require the unanimous approval of
        the Executive Committee. The Board will form an Audit Committee with 3 members, consisting of 1 director appointed by Management
        Shareholders (which initially shall be Mr. Pemble), 1 director appointed by Sponsor and 1 director appointed by Significant Shareholder.
        The Audit Committee will be responsible for overseeing financial reporting of the Group and approving the financial statements
        of any Group Company. All decisions of the Audit Committee will require the approval of a majority of the members thereof.

         

        ·     The
        Board will form a Remuneration Committee with 3 members, consisting of the co-chairmen of the Board and 1 director appointed by
        Management Shareholders (which initially shall be Ms. Silverberg). The Remuneration Committee will be responsible for determining
        or modifying the compensation of, or any significant changes to the terms of appointment of, the CEO, the CFO and the COO. It will
        also be responsible for determining the size and composition of the pool of compensation available for distribution to eligible
        managers (the composition of such eligible managers at and following the closing of the acquisition of Healthy shall be proposed
        by the CEO, subject to approval by the Remuneration Committee). The allocations of such pool among the eligible managers shall
        be solely the decision of the CEO. All decisions of the Remuneration Committee will require the approval of a majority of the members
        thereof.

         

	Management	
        The CEO, Sponsor and Significant Shareholder shall have the
        sole right to jointly nominate (i) the COO of the Company after the 1st anniversary of the closing of the proposed transaction
        and (ii) the CFO of the Company, in each case subject to the approval of the CEO (so long as Ms. Lipson is the CEO). The CEO, Sponsor
        and Significant Shareholder shall jointly nominate the COO of the Company as soon as possible after the 1st anniversary of the
        closing of the proposed transaction.

         

        The CEO shall have the right to nominate any manager or officer
        who directly reports to the CEO; provided that the Board shall have the right, by majority vote, to remove any manager or
        officer who directly reports to the CEO if Underperformance has occurred.

         

        The Board shall have the right, by majority vote, to remove
        the general manager of each of the Qingdao, Guangzhou, Haidian, Puxi and Pudong projects if Underperformance has occurred.

         

        The Board shall be responsible for setting the overall strategy
        of the Company, which shall be based on an overarching value of commitment to the quality of care, and for oversight of the management
        of the Company. Other than matters that are reserved for the Board set forth in the section entitled “Reserved Matters”
        below, all decisions regarding day-to-day management of the Group shall be delegated to the senior management team, subject to
        the oversight of the Board and as delegated by it to the Executive Committee, Audit Committee and Remuneration Committee as set
        forth

 

    	3

    	 

    

 

	 	above.

                                             

	Post-Closing

 Matters	
        Upon the closing of the proposed transaction:

         

        ·     The
        Board will create a new employee incentive program; such plan will include, without limitation, cash and equity incentive
        programs at such levels and on such terms that are no less favorable to employees than the current programs;

         

        ·     The
        Board shall appoint a CFO within 100 days after the closing; and

         

        ·    
         The         Board shall appoint one of the Big Four audit firms as the Company’s independent auditor.

         

	Monitoring Fees	In consideration of services to be provided by Sponsor and Significant Shareholder to the Group, Parent, affiliates of Sponsor and affiliates of Significant Shareholder will enter into an agreement at the closing of the proposed transaction providing for the payment by Parent of a periodic monitoring fee in an aggregate annual amount equal to US$250,000 per year plus reasonable out-of-pocket expenses (not to exceed US$25,000 in the aggregate per year) to each of (i) Sponsor or its affiliates and (ii) Significant Shareholder or its affiliates in consideration of services to be provided to the Group.  No fees for additional services to be provided by Sponsor and Significant Shareholder or its affiliates to the Group will be charged, unless agreed to in advance in writing by the CEO.

                                 

	Reserved Matters 	
        The following matters with respect
        to the Group will require unanimous approval of the Board:

         

        ·     Any
        amendment, alteration or modification of the constitutional documents of any Group Company.

         

        ·     Any
        change of the rights, preferences or privileges of the LP Interest or securities of any Group Company.

         

        ·     Any
        alteration of the country of incorporation, registration or corporate form of any Group Company.

         

        ·   
         Change         of Ms. Roberta Lipson as CEO during the three-year period beginning January 1, 2014, unless (i)
        Underperformance has occurred,         (ii) Ms. Lipson directly or indirectly transfers more than 20% of her post-closing LP
        Interests prior to an IPO or (iii) Ms. Lipson         (A) has violated, or caused any Group Company to violate, any
        applicable law or regulations or (B) has committed fraud (in each         case of (A) and (B), as finally adjudicated by a
        court of competent jurisdiction); provided that in the case of (A), such         violation has resulted in or would
        reasonably be expected to result in (x) a material adverse effect to any Group Company whose         revenue, profit or
        assets represent no less than 10% of the Group’s consolidated revenue, profit or assets or (y) a material
        adverse effect to the Group, taken as a whole. (For the avoidance, of doubt, this means that if (i)

         

 

    	4

    	 

    

 

	 	
        Underperformance has occurred,
        (ii) Ms. Lipson sells more than 20% of the post closing LP Interests prior to an IPO or (iii) Ms. Lipson has violated, or caused
        the Group to violate, any applicable law, regulation or regulations or has committed fraud as set forth above, she can be removed
        as CEO with a simple majority vote of the Board (“Violation of Law Removal”).)

         

        ·      Any
        capital expenditure for a category3 in each market 10%
        below or in excess of the annual budget for such category in such market approved by the Board.

         

        ·      Any
        merger or consolidation, or sale of all or substantially all of the assets of any Group Company, other than pursuant to the exercise
        of drag along rights described under “Exit Provisions” below.

         

        ·      Instituting
        any proceeding in connection with re-organization, insolvency, winding up, liquidation, bankruptcy, administration, receivership,
        dissolution or similar event of any Group Company.

         

        ·      Adopting
        or amending any equity incentive plan.

         

        ·      Redeeming
        or repurchasing the LP Interest of Parent.

         

        ·     Any
        transaction with any shareholder or a party affiliated with a shareholder, other than transactions (i) set forth in “Monitoring
        Fees” above, (ii) between Parent and any other Group Company or (iii) between any Group Company and CML that involve payment
        by or to any Group Company for any fiscal year in an aggregate amount not in excess of 110% of the aggregate payment made in the
        previous fiscal year by or to the Group in any of the loan, equipment and consumables categories.

         

        ·      Any
        issuance of LP Interests or other equity securities, other than (i) pursuant to equity incentive plans approved by the Board and
        (ii) as described under “Primary Capital Financing” below.

         

        ·      Any
        agreement or understanding reached within 12 months after the closing of the proposed transaction regarding the spin-off of CML;
        provided that Sponsor, Significant Shareholder and Management Shareholders shall negotiate in good faith regarding the terms
        and conditions of such spin off during such 12 month period. For the avoidance of doubt, agreements or understandings reached after
        the date that is 12 months after the closing of the proposed transaction regarding the spin-off of CML shall not require unanimous
        approval of the Board.

         

        For the avoidance of doubt, with
        respect to the enforcement of any right of the Company against any shareholder that would require the Board’s approval, the
        Board representatives of such shareholder shall recuse themselves from board deliberations

 

 

3
Category to include maintenance, construction, equipment, new clinic and IT.

 

    	5

    	 

    

 

	 	
        of such enforcement actions.

         

	Voting	
        Each LP Holder and other holders
        of LP Interests and GP Interests will vote their interests in accordance with the decisions of the Board.

         

	Transfer

 Restrictions	
        No LP Holder shall directly or indirectly transfer any of its,
        his or her LP Interests prior to an IPO, unless (i) it, he or her has first complied with the requirements described under “Right
        of First Offer” below or (ii) such transfer is pursuant to an employee incentive repurchase program established by the Board
        to provide liquidity for management members and doctors and approved by the Board.

         

        If Mr. Pemble or Ms. Silverberg directly or indirectly transfers
        more than 20% of his or her post-closing LP Interests prior to an IPO, he or she can be removed as a director of any Group Company
        with a simple majority vote of the Board.

         

	Right of First

 Offer	
        Prior to an IPO, any valid direct or indirect transfer of LP
        Interests by Sponsor, Management Shareholders or Significant Shareholder (other than permitted transfers, transfers in connection
        with an IPO or consequent upon the exercise of drag along rights described under “Exit Provisions” below) shall be
        subject to a customary right of first offer by the other parties on a pro rata basis; provided that in the event of a valid
        direct or indirect transfer of LP Interests by a Management Shareholder, the transferring Management Shareholder's LP Interests
        shall first be subject to a right of first offer by the other Management Shareholders on a pro rata basis, and any LP Interests
        with respect to which such right was not exercised will then be subject to the customary right of first offer by the other parties
        on a pro rata basis.

         

        In the event any of Sponsor, Management Shareholders or Significant
        Shareholder does not wish to exercise its, his or her full pro rata share of the right of first offer, the other parties may take
        up the unacquired allocation of each non-purchasing party, on a pro rata basis.

         

	Pre-Emptive

 Rights	
        In connection with any direct or indirect issuances
        of LP interests, equity-linked or voting securities by Parent or the Company (“New Interests”), each LP Holder
        shall have the right to subscribe for such New Interests in proportion to its ownership of Parent, subject to exceptions for issuances
        in an IPO, issuances to employees pursuant to any employee stock ownership plan or other incentive or profit sharing program approved
        by the Board, issuances to sellers or partners in connection with acquisitions or strategic partnership by any Group Company, and
        other customary exceptions.

         

        In the event that Sponsor or Significant Shareholder
        does not wish to exercise its full pro rata share of pre-emptive rights, the other party may take up the unacquired allocation
        of such non-subscribing party.

         

	Repurchase

 of Employee 	Prior to an IPO, the Board shall consider in good faith for the Parent to purchase (i) up to 25% of the LP Interests and/or options held by each management member and doctor (other than Ms. Roberta Lipson, Ms. Elyse Silverberg and Mr. Lawrence 

 

    	6

    	 

    

 

	Shares	
        Pemble) at the time of such purchase, upon such management member’s
        or doctor’s written request and (ii) with respect to any management member (other than Ms. Roberta Lipson, Ms. Elyse Silverberg
        and Mr. Lawrence Pemble) who has rolled more than 50% of his or her equity in connection with the proposed transaction (the amount
        by which the percentage of his or her equity interest rolled over in connection with the proposed transaction in the total equity
        interest owned by such person immediately before the consummation of the proposed transaction exceeds 50%, the “Excess
        Amount”), up to the Excess Amount of his or her LP Interests and/or options, in the case of (i) and (ii), at a price
        equal to the fair market value of such LP Interests or options as determined in good faith by the Board; provided that,
        in the case of (i), the Board shall only consider for Parent to purchase over a five-year period up to an aggregate of 25% of all
        of the outstanding LP Interests and/or options held by such management member or doctor; provided, further, that,
        in the case of (i) and (ii), the Board shall, in no event, be required to consider for Parent to purchase any such LP Interests
        and/or options if such purchase would reasonably be expected to adversely impact the future cash flow or operations of the business
        of Parent.

         

	Exit

 Provisions	
        If an IPO of the Company on an internationally recognized stock
        exchange does not occur by the 3rd anniversary of the closing of the proposed transaction, Sponsor shall have the right
        from such 3rd anniversary (as may be suspended by the proviso below, the “Sponsor Drag Initiation Date”)
        to require Management Shareholders and Significant Shareholder to transfer all of their LP Interests to any third party to whom
        Sponsor wishes to transfer all of its LP Interests at the same price and on the same terms; provided that such 3 year period
        shall be suspended if good faith preparation for a bona fide IPO on an internationally recognized stock exchange has commenced,
        including that the Company has appointed underwriter(s) of international reputation for such IPO, by such time until the earlier
        of (i) the termination or abandonment of such IPO and (ii) the date that is 9 months after the 3rd anniversary of the
        closing of the proposed transaction; provided, further, that Management Shareholders and Significant Shareholder
        shall have a right of first offer to purchase the LP Interests proposed to be sold by Sponsor. Sponsor shall have the right to
        transfer its LP Interests to a third party at terms more favorable to Sponsor than those offered by Management Shareholders or
        Significant Shareholder, in which case, the drag along right of Sponsor shall apply; provided that, prior to the 5th
        anniversary of the closing of the proposed transaction, the drag along right of Sponsor shall only apply if the per LP Interest
        price in such drag along sale is at least equal to 2.0 times the per LP Interest price paid in the proposed transaction.

         

        If an IPO of the Company on an internationally recognized stock
        exchange does not occur by the 5th anniversary of the Sponsor Drag Initiation Date (such date, the “Significant
        Shareholder Drag Initiation Date”), Significant Shareholder shall have the right to require Management Shareholders and
        Sponsor to transfer all of their LP Interests to any third party to whom Significant Shareholder wishes to transfer all of its
        LP Interests at the same price and on the same terms; provided that Management Shareholders and Sponsor shall have a right
        of first offer to purchase the LP Interests proposed to be sold by Significant Shareholder. Significant Shareholder shall have

 

    	7

    	 

    

 

	 	
        the right to transfer its LP Interests to a third
        party at terms more favorable to Significant Shareholder than those offered by Management Shareholders or Sponsor, in which case,
        the drag along right of Significant Shareholder shall apply.

         

	Exit

 Acknowledgement	
        Sponsor, Management Shareholders and Significant
        Shareholder acknowledge that Sponsor will be looking for medium-term liquidity and each of Sponsor, Management Shareholders and
        Significant Shareholder shall use its reasonable best efforts to facilitate (i) an IPO of the Company within 5 years after the
        closing of the proposed transaction, and (ii) if an IPO is not achieved within such 5 years, a sale of the Company that maximizes
        shareholder value for all Sponsor and the other shareholders of Parent.

         

	Tag-Along

 Right	
        Prior to an IPO, Sponsor, Management Shareholders
        and Significant Shareholder shall each have the right to sell its LP Interests to any third party or other LP Holder to whom any
        other of them wishes to transfer LP Interests at the same price and on the same terms on a pro rata basis.

         

	Primary

 Financing

 Commitment	
        Concurrently with the execution of the merger agreement
        providing for the acquisition of Healthy, Sponsor and Significant Shareholder are providing separate equity commitment letters
        in respect of their respective commitment, on the terms and subject to the conditions set forth in the relevant equity commitment
        letter and the form subscription agreement attached thereto, to purchase additional LP interests of Parent (i) initially in an
        aggregate amount equal to US$90 million at the valuation of $19.50 per LP Interest and (ii) subsequently in an aggregate amount
        equal to US$40 million on the same valuation of $19.50 per LP Interest or, if the definitive agreement for such subscription is
        executed more than 6 months after the closing of the proposed transaction, on fair market valuation at such time.

         

        Notwithstanding anything herein to the contrary, all rollover
        management shareholders shall have the right to participate in the Primary Financing Commitment, on a pro rata basis (on the basis
        of the intended capital structure immediately upon closing, as reflected on page 1 of this term sheet), with respect to any LP
        interests issued at a price of $19.50 per unit (i.e., the initial subscription and the subsequent subscription effected within
        6 months after the closing date of the proposed transaction).  Sponsor and Significant Stockholder shall use commercially
        reasonable efforts to help arrange financing for such subscription by such rollover management shareholders.

         

        Concurrently with the consummation of the Primary Financing
        Commitment, Parent shall issue options to the rollover management shareholders to purchase additional LP Interests, such that their
        pro rata ownership of Parent’s equity shall not be diluted by the difference between the issuance price and the fair market
        valuation of such LP Interests, not taking into account any participation by such rollover management shareholders in the Primary
        Financing Commitment. The LP Holders hereby acknowledge that the fair market valuation of per LP Interest within 6 months after
        the closing of the proposed transaction equals to the Merger Consideration.

         

 

    	8

    	 

    

 

	Information

 Rights	
        Each LP Holder will have customary information and
        inspection rights, including reasonable access to the Company’s senior management team, premises and books and records, subject
        to such LP Holder holding at least 5% of the outstanding LP Interests. In principle this access will occur at the monthly executive
        review meeting. If additional access is necessary, appointments will be booked with reasonable advance notice through the CEO’s
        administrative assistant which shall not be unreasonably delayed or withheld.

         

	Independent

 Investigation	
        Each party is an informed and sophisticated participant in the
        transactions contemplated hereby and has undertaken such investigation as it has deemed necessary in connection the transactions
        contemplated hereby.

         

        Each party acknowledges that it is relying on its own investigation
        and analysis in entering the transactions contemplated hereby and has consulted its own legal, tax, financial and accounting advisors
        to determine the merits and risks thereof.

	 	 
	Confidentiality	
        The provisions of this term sheet and the fact of its existence
        are confidential and, except as required by applicable law, regulation or rule of applicable securities exchange, no party shall
        directly or indirectly, disclose, reveal, divulge, publish or otherwise make known to any person any of the provisions of this
        term sheet or the fact of its existence save that each party may make disclosure to those of its officers, employees and advisers
        who need to be aware of the provisions of this term sheet in order to facilitate the matters contemplated herein; provided
        that the party relying on this exception shall be and remain responsible for the failure by any such person to whom disclosure
        is to be made to maintain the confidentiality of this term sheet and the fact of its existence.

         

	Governing

 Law	
        This term sheet shall be governed by the laws of Delaware.

         

	 	 
	Legal and

 Binding	This term sheet is not intended, and shall not be deemed, to create any binding obligation between the parties to this term sheet.  Except for sections entitled “Confidentiality” and “Governing Law” and this section, which shall constitute a legally binding and enforceable contract between the parties to this term sheet, none of the parties shall be bound in any way in connection with this term sheet unless and until the parties execute a definitive agreement, and then shall be bound only in accordance with the terms of such agreement.    

 

    	9

    	 

    

 

Schedule I

Underperformance

 

“Underperformance” means:

 

(i) with respect to the CEO, that the Company has missed its
operating EBITDA4 thresholds on a cumulative basis over
any two successive years from January 1, 2014 by more than 25% in the aggregate other than due to Force Majeure. The parties agree
that the operating EBITDA thresholds shall be set based on the lower of (i) the management five-year plan provided to Sponsor
and Significant Shareholder and (ii) the Company’s annual budget approved by the Board;

 

(ii) with respect to the managers or officers who directly report
to the CEO, that the Company has missed the individual cash bonus key performance indicator thresholds set by the CEO as part of
the bonus program pursuant to discussions with the Remuneration Committee on a cumulative basis over any two successive years from
January 1, 2014 by more than 25% in the aggregate other than due to Force Majeure; and

 

(iii) with respect to the general manager of each of the Qingdao,
Guangzhou, Haidian, Puxi and Pudong projects, the project for which such general manager is responsible has missed its Revenue
threshold on a cumulative basis over any two successive years from January 1, 2014 by more than 25% in the aggregate other than
due to Force Majeure. The parties agree that the Revenue thresholds shall be set based on the lower of (i) the management five-year
plan with respect to such project provided to Sponsor and Significant Shareholder and (ii) the Company’s annual budget with
respect to such project approved by the Board.

 

"Force Majeure" means the missing of operating
EBITDA, key performance indicator thresholds or Revenue threshold, as applicable, solely due to any effect, event, circumstance,
occurrence or change arising out of acts or terrorism or sabotage, the outbreak, escalation or worsening of hostilities, man-made
disasters, natural disasters or other acts of god, including disease outbreaks that keep patients away from the hospital, and change
in government policies or enforcement thereof that did not have a disproportionate effect on the Company as compared to other companies
in the operation of premium private or VIP and International departments of Class IIIA hospitals and/or clinics in markets in which
the Group has hospitals or clinics.

 

 

4 Operating EBITDA excludes one-time items.

 

    	10

    	 

    

  

SCHEDULE A-1

 

As of February 17, 2014

 

	Stockholder	 	Address/Facsimile	 	Residence	 	Common Stock 

    Owned	 	 	Class B 
 Common
    Stock 
 Owned	 
	Roberta Lipson	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	232,352	 	 	 	570,000	 
	Benjamin Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	10,800	 	 	 	0	 
	Daniel Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	0	 	 	 	30,000	 
	Jonathan Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	0	 	 	 	30,000	 
	Ariel Benjamin Lee Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	0	 	 	 	30,000	 
	Elyse Silverberg	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	225,106	 	 	 	390,750	 

 

    	 

    	 

    

 

	Stockholder	 	Address/Facsimile	 	Residence	 	Common
    Stock 
 Owned	 	 	Class
    B 
 Common Stock 
 Owned	 
	Lawrence Pemble	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	USA	 	 	83,956	 	 	 	111,750	 
	Significant Stockholder	 	Qiao Yang, Shanghai Fosun Pharmaceutical Group Co., Ltd. 
  
9th Floor, No.2 East Fuxing Road, Shanghai 200010, PRC 
  
Tel: +86 21 23138000*8185/23128185 
  
Fax: +86 21 23138127 
	 	Hong Kong	 	 	3,157,163	 	 	 	0	 

 

    	 

    	 

    

 

Schedule A-2

  

	Stockholder	 	Address/Facsimile	 	Rollover
    Shares	 	 	Parent
    Interests	 
	Roberta Lipson	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	 	629,882	 	 	 	629,882	 
	Benjamin Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	 	8,640	 	 	 	8,640	 
	Daniel Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	 	30,000	 	 	 	30,000	 
	Jonathan Lipson Plafker Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	 	30,000	 	 	 	30,000	 
	Ariel Benjamin Lee Trust	 	c/o Chindex International, Inc.
 4340 East West Highway
 Bethesda, MD 20814
 Attention: Chief Executive Officer and Corporate Secretary
 Facsimile No.: 310-215-7777	 	 	30,000	 	 	 	30,000	 
	Significant Stockholder	 	Qiao Yang, Shanghai Fosun Pharmaceutical Group Co., Ltd. 
  
9th Floor, No.2 East Fuxing Road, Shanghai 200010, PRC 
  
Tel: +86 21 23138000*8185/23128185 
  
Fax: +86 21 23138127 
	 	 	3,157,163	 	 	 	3,157,163

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]